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Needle exchange client holding referral to medical care, Bishkek, Kyrgyzstan
Outside of Africa, UNAIDS estimates that
one of three HIV infections is now due to
injecting drug use. Contaminated injection
equipment accounts for the largest share 
of HIV infections in China, Indonesia,
Malaysia, Ukraine, the Baltic States, the
Caucasus, Central Asia, much of South 
and Southeast Asia, and the Southern Cone
of South America. 
Founded in 1995, the International
Harm Reduction Development Program
(IHRD) of the Open Society Institute (OSI)
works to reduce HIV and other harms relat-
ed to injecting drug use, and to press for
policies that reduce stigmatization of illicit
drug users and protect their human rights.
IHRD, which has supported more than 200
programs in Central and Eastern Europe,
the former Soviet Union, and Asia, bases its
activities on the philosophy that people
unable or unwilling to abstain from drug
use can make positive changes to protect
their health and the health of others. Since
2001, IHRD has prioritized advocacy to
expand availability of needle exchange, opi-
ate substitution treatment, and treatment
for HIV; to reform discriminatory policies
and practices; and to increase the political
participation of people who use drugs and
those living with HIV.
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International Harm Reduction Development 
Program: Mission and Strategies
In increasing numbers of countries in Asia and the former Soviet Union, HIV epidemics
are driven by injecting drug use. UNAIDS has noted that the Russian Federation’s 
HIV epidemic is the fastest growing in the world: as many as 1.2 million people there
are estimated to be living with HIV, more than in the United States and Canada 
combined. Virtually all were infected in the last eight years. Eighty percent of all regis-
tered HIV cases are among those under the age of 30. Almost nine in ten are injecting
drug users (IDUs). 
Reducing Harm Through Service
Needle exchange, substitution treatment, 
overdose prevention, and legal support
An overwhelming body of scientific evidence
supports the efficacy of needle exchange and
opiate substitution treatment in reducing
HIV risk. Services that IHRD has supported
include:
• needle exchange programs across
Central and Eastern Europe and the
former Soviet Union;
• substitution treatment with methadone
or buprenorphine in countries includ-
ing Albania, Kyrgyzstan, Lithuania, and
Ukraine;
• the formation of harm reduction net-
works in Central and Eastern Europe,
Russia, and Central Asia to help 
programs exchange information and
advocate for change;
• prison-based harm reduction pro-
grams, including needle exchange 
in Kyrgyzstan and Moldova;
• counseling and outreach efforts to
reach drug users, their families, and
friends with accurate information
about HIV, hepatitis C, and overdose;
• legal services programs to help fight
discrimination and prevent legal
abuses; and
• trainings for police, HIV physicians,
drug treatment specialists, and harm
reduction program staff.
Reducing Harm Through 
Technical Assistance
New models of treatment for 
HIV and drug dependence
Support from the Global Fund to Fight 
AIDS, Tuberculosis and Malaria (GFATM)
and from bilateral and multilateral 
donors such as the UK’s Department for
International Development (DFID) and the
World Bank has greatly increased funding
available for harm reduction. The need for
assistance in scaling up such services at the
country level, however, remains acute.
Technical assistance provided by IHRD
has facilitated:
• expansion of antiretroviral treatment
(ARV) in Russia, and the develop-
ment of the first HIV treatment pro-
tocols that include drug users;
• integration of programs providing
HIV prevention, HIV treatment, opi-
ate substitution treatment, and care
for tuberculosis in Ukraine;
• support in the preparation and imple-
mentation of Global Fund grants 
on harm reduction in Azerbaijan,
Georgia, Moldova, Russia, Tajikistan,
Thailand, and Ukraine; and
• bilateral funding of harm reduction
initiatives in Central Asia, and moni-
toring to ensure that the money is
used appropriately.
Reducing Harm Through Advocacy
Policies based on evidence rather than ideology
Harm reduction programs cannot be effec-
tive if fear of harassment, arrest or incar-
ceration makes drug users reluctant to use
them. IHRD has worked with policymakers
at local, provincial, national, and interna-
tional levels to: 
• encourage the United Nations and
national governments to support
proven measures such as syringe
exchange and substitution treatment
at the UN Commission on Narcotic
Drugs, the Human Rights Commission,
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the UNAIDS Programme Coordinating
Board, and in national plans;
• highlight the role that incarceration
and forced institutionalization play 
in accelerating the HIV epidemic,
and the policy changes that can
reduce overcrowding, disease risk,
and human rights violations;
• increase funding for and political
commitment to the provision of HIV
prevention, treatment, and care for
IDUs; and 
• sponsor or co-sponsor policy dia-
logues, conferences, satellite ses-
sions, and study tours to explore 
solutions and demonstrate lessons
learned in harm reduction.
Reducing Harm Through
Community Organizing
Support for drug users and 
people living with HIV 
More than two decades of HIV have shown
that so-called “hard to reach” populations
are often their own best advocates. Despite
the importance of involving those directly
affected in the formation of AIDS policy,
drug users often have been excluded from
even those mechanisms that are supposed
to increase the participation of people living
with HIV.
IHRD has supported active participa-
tion of affected communities by offering:
• funding and technical support to
organizations of drug users and 
people with HIV in 13 countries of
Eastern Europe, the former Soviet
Union, and Asia. Groups work on
issues as varied as overdose preven-
tion, HIV treatment advocacy, and
media campaigns; 
• sponsorship of participation of people
who use drugs and people with
HIV in international conferences as
well as in regional and national con-
ferences in Asia and the former
Soviet Union;
• work with groups such as the
European AIDS Treatment Group, 
the Global Network of People Living
with HIV/AIDS (GNP+), and the
Collaborative Fund for HIV Treatment
Preparedness/International Treatment
Preparedness Coalition on programs
to increase HIV treatment literacy,
ensure transparent and effective pro-
curement of ARV, and challenge the
systematic exclusion of drug users
from care; and
• training and grants to support com-
munity mobilization, monitoring of
the Global Fund and other HIV pro-
grams, and documentation of human
rights abuses.
For more information on the International
Harm Reduction Development Program, 
see www.soros.org/harm-reduction
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Harm reduction program in Togliatti, Russia
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UNAIDS, in its AIDS Epidemic Update: December 2005, put
the total number of HIV-positive people in the world at 40.3
million and estimated that 5 million were infected in 2005
alone. These numbers are horrifying, but not surprising.
Although for years we have known how to prevent HIV trans-
mission, we have done a terrible job in translating knowl-
edge into action. Jim Yong Kim, WHO’s outgoing director for
HIV/AIDS, said the 5 million new cases in 2005 showed that
global HIV prevention efforts have “failed, failed, failed.”
The reasons why these efforts have “failed”
are now familiar: lack of political will and
leadership, discrimination against people
living with HIV and those vulnerable 
to infection, limited access to treatment,
and substandard efforts to provide HIV 
prevention services to those in need. None 
of these issues is easy to address, especially
in the resource-poor countries that continue
to bear the brunt of the HIV epidemic. 
An important step toward improving
global prevention is to know where, how,
and why HIV is spreading—and what, 
if anything, is being done to halt the epi-
demic. This report provides a snapshot of
some key developments in HIV prevention
for injecting drug users (IDUs) in 2005.
IDUs comprise 10 percent of all global HIV
cases, a number that rises to 30 percent out-
side of sub-Saharan Africa. The fact that
needle sharing is an especially efficient
method of transmitting HIV means that
epidemics among IDUs are also explosive.
Once HIV is introduced into a drug-using
network, HIV prevalence can surge from
zero to 50 percent in a matter of months. 
From the Directors
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Just as stark as HIV prevalence surveys,
however, are studies showing that compre-
hensive harm reduction interventions can
drastically cut rates of HIV infection among
IDUs. In few other areas of HIV prevention
has the evidence been so clear. Increased
access to needle/syringe exchange and opi-
ate substitution treatment sharply reduces
IDUs’ likelihood of contracting HIV and
greatly improves their health and public
health in general. 
Nevertheless, harm reduction remains
controversial in most of the world.
Policymakers frequently claim that services
such as needle exchange encourage illicit
drug use or fail to adequately punish those
who break the law. Others claim that any
approach that does not require abstinence
from drug use represents a moral failure.
This argument ignores the moral costs of
failure to make available needle exchange,
substitution treatment or overdose preven-
tion, thus causing illnesses and deaths that
might easily have been prevented. 
IDUs comprise the largest share of 
total HIV cases in some 20 nations of Asia
and the former Soviet Union. In countries
such as Russia and Ukraine, the epidemic,
though young, can fairly be described as
fully established, and AIDS deaths have
already begun their devastating impact on
individual health and economic develop-
ment. In others, such as the Central Asian
republics and certain countries in Southeast
Asia, HIV prevalence and AIDS cases
remain comparatively low, but are steadily
rising among IDUs and other vulnerable
populations. 
Efforts to address injection-driven 
epidemics vary widely, from repressive law
enforcement measures to those informed
by respect for human rights or public health
Outreach worker and volunteers, Bishkek, Kyrgyzstan
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evidence. With support from international
and domestic organizations, drug users and
their allies are mobilizing to articulate their
needs and demand appropriate policies and
resources. Grants from the Global Fund 
to Fight AIDS, Tuberculosis and Malaria
were particularly important in initiating or
expanding harm reduction services in 2005.
Funds coming from Geneva, however, are
only as effective as those programs working
to turn them into harm reduction services at
the country level. Here, as these pages show,
much remains to be done.
This report focuses on countries where
IHRD or our local partners work, and in no
way provides a complete record of global
harm reduction developments. Important
harm reduction organizations and networks
operate across Asia and Latin America 
without support from or engagement with
the Open Society Institute. Further, many
countries where IDUs are not a majority of
HIV cases—including Burma, Cambodia,
India, and Pakistan—are excluded here, 
but nonetheless have significant numbers
of HIV infections among IDUs and impor-
tant initiatives underway by harm reduction
advocates and service providers. Despite 
the narrow focus of the report, we hope 
the information will be useful to all those
seeking to scale up prevention, treatment,
and human rights protection for IDUs. 
More than the health of drug users 
is at stake. In 2005, many countries with 
epidemics concentrated primarily among
IDUs reported increasing numbers of HIV
cases among women infected sexually.
Reluctance to provide drug users with 
services has proved to be a punishment
delivered also to the families of drug users,
and to whole communities. The appropriate
response as HIV epidemics become less
concentrated, however, is not to raise alarm
about “generalizing” epidemics and to turn
away from efforts targeted to IDUs. Rather,
countries must reckon honestly with the
fact that the women and children who 
represent the new wave of infections are
themselves primarily the sexual partners
and children of people who use drugs.
General AIDS awareness messages are no
substitute for appropriate HIV prevention
and treatment services for IDUs. 
As the philosopher George Santayana
observed a century ago, “Those who cannot
remember the past are condemned to repeat
it.” We hope that that this report will help 
us recognize the missed opportunities of
the past, and galvanize more impressive
steps in the future.
Kasia Malinowska-Sempruch, Director
Daniel Wolfe, Deputy Director
International Harm Reduction Development Program
HIV treatment activists in Moscow, Russia
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The world’s largest supporter of HIV 
programs, the U.S. government, does not
allow its financial assistance to be used to
pay for sterile injection equipment. Some
U.S. officials in 2005 also sought to limit
international commitments to harm reduc-
tion, working to strike language about 
sterile syringes from United Nations 
documents and suggesting that recipients
of U.S. aid should also refrain from using
monies from other sources for needle and
syringe programs. In Europe, by contrast,
governments presented a virtually united
front in 2005 in support of harm reduction.
Meetings of UN bodies, where global 
consensus is sought, became the battlefield
where these competing views were
expressed.
No Condoms, Needles, or 
Human Rights for Drug Users 
at the 48th Session of the
Commission on Narcotic Drugs
Although little-known among HIV activists,
the Commission on Narcotic Drugs (CND)
shapes global AIDS policy in the increasing
number of countries with injection-driven
HIV epidemics. The 53-member body sets
the agenda for the UN Office on Drugs and
Crime (UNODC), a co-sponsor of UNAIDS
and the member of the UN “family” desig-
nated the primary source of technical 
assistance for HIV prevention among 
IDUs. The 2005 meeting of the CND, held 
in March in Vienna, was particularly impor-
tant because HIV prevention among drug
users was a special focus of debate.
Harm Reduction Developments: 
International Policy
Injection-driven HIV epidemics are frequently found in
nations that rely on assistance from abroad to address 
public health needs. As a result, the inclination and ability
of individual countries to support harm reduction are 
greatly influenced by the policies of multilateral institutions
and wealthy nations. 
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The anti–harm reduction campaign by
the United States began well in advance 
of the meeting itself. In November 2004,
U.S. Assistant Secretary of State Robert
Charles visited UNODC Executive Director
Antonio Maria Costa. The day after his visit,
Costa sent a mea culpa to Charles pledging
that UNODC would be “even more vigilant”
in policing web pages and publications for
the term “harm reduction.” Shortly there-
after, a senior staff member at UNODC sent
an email to regional offices, reminding
them to avoid positive references to needle
exchange or harm reduction in UNODC
printed and electronic statements. 
Efforts by the Bush administration to
make its particular ideology into the global
standard elicited strong reactions from
NGOs and governments. A coalition of
groups including Human Rights Watch, the
Canadian HIV/AIDS Legal Network, the
International Harm Reduction Association,
the Asian Harm Reduction Network, Gay
Men’s Health Crisis, the European AIDS
Treatment Group, and OSI circulated a sign-
on letter endorsed by more than 350 organ-
izations and individuals from 56 countries
urging that the U.S. position be challenged.
OSI President Aryeh Neier, in an opin-
ion piece in the International Herald Tribune,
warned that American policies failed to
grasp the global realities of the world’s HIV
crisis, while editorials in the New York Times
and the Washington Post condemned the
Bush administration for “flat-earthism” and
ideological bullying. “The United States
should help pay for these important pro-
grams,” the Times concluded. “If it cannot
bring itself to do so, it should at least allow
the rest of the world to get on with saving
millions of lives.” 
Governments also responded. In the
debate on HIV prevention at the CND meet-
ing, 17 of 30 speakers, including those rep-
resenting Australia, the European Union,
and the United Kingdom, directly supported
needle exchange or harm reduction. Former
opponents such as China, Iran, Libya, and
Sweden indicated support or openness 
to further exploration of the approach.
Brazil proposed a resolution, “HIV/AIDS
and the Right to Health,” that called for 
the increased availability of clean needles
for drug users. The proposal won support
from a group of Latin American and
Caribbean nations and most countries of
the EU, as well as from Canada, Iran, and
Nigeria, among others. 
While these efforts heightened atten-
tion to the U.S. government’s obstructive
position, they did not carry the day. In pub-
lic, U.S. drug czar John Walters refrained
from attacking needle exchange, and U.S.
officials voiced strong support for substitu-
tion treatment. In private, though, delegates
from other countries reported that U.S. 
representatives remained immovable,
insisting that any mention of needle
exchange, harm reduction, or even the word
“harm” be deleted from all CND resolutions.
Washington representatives also deemed
mention of the human rights of drug users
unacceptable, and consistently sought to
replace the term “HIV prevention” with ref-
erences to drug abuse prevention and treat-
ment. Negotiating with the United States, a
Latin American delegate recalled later, was
“like taking a beating.” 
In the end, the United States prevailed.
No resolution at the CND mentioned needle
exchange, condoms, or the human rights of
drug users.
UNAIDS Prevention Strategy, Including
Clean Needles, Wins U.S. Approval
Having witnessed successful U.S. efforts 
to remove all mention of sterile injec-
tion equipment from resolutions at the
Commission on Narcotic Drugs (CND) in
March 2005, advocates were prepared for
another battle over the adoption of the UN’s
I would like to raise a point about injecting drug
users. I come from Russia—a country where
[more than] 80 percent of HIV cases are related 
to injecting drug use and access to adequate 
HIV prevention for this group represents the 
central element of effective HIV prevention in
general. While some countries in our region 
can demonstrate good examples of scaling up
services for IDUs, as promised in 2001, my own
country is not among them.
Ironically, the scale of services such as needle
exchange in Russia has been shrinking rather
than increasing over the last five years. . . .
Substitution treatment, which is high on the 
list of evidence-based prevention strategies, is
illegal in Russia. There is no national HIV plan to
ensure inclusion of drug users into prevention
programs. Hundreds of thousands [are impris-
oned] for minor drug offenses, and no prevention
is provided within prison walls, where IDUs are
even more vulnerable to HIV. All this illustrates
how my country effectively fails to adhere to its
2001 commitments.
But my country is not unique in this regard. 
We all have read the appalling figures in the
Secretary General’s report: in 2003, targeted 
prevention services reached only 16 percent of 
sex workers and only 5 percent of IDUs. So we
should ask ourselves today: Why is this happen-
ing? Why are highly effective and evidence-based
interventions such as needle exchange and 
substitution treatment not taken up by our gov-
ernments, as promised?
Is it because drug users and sex workers are
considered “marginal” and disposable members
of societies, and not even thought of as eligible
for human rights protection?
Is it because of the legal barriers and unwilling-
ness to challenge them? Do governments fear
becoming unpopular among the electorate and
therefore prefer to sacrifice a detested part of 
the population rather than to provide leadership
in building humane and fair societies?
Is it because the countries possess few
resources or, more likely, little desire to allocate
any resources for these politically difficult inter-
ventions?
Is it because some governments, such as 
the United States, not only restrict access to effec-
tive prevention for groups such as drug users and
sex workers within their own country, but also
impose such policies on poor and economically
dependent countries?
Is it because countries place greater priority on
other international commitments, such as drug
conventions that are often interpreted by govern-
ments as justification to employ a simple and
straightforward approach to drug users: catch
them and lock them up? In many countries this
approach is implemented much more vigorously
than promised HIV prevention. 
Is it because in most democratic societies 
drug users or sex workers are not even invited
when important discussions directly influencing
their lives such as this one are taking place?
And honestly, is this happening because at 
the end of the day nobody will be held account-
able for the mass murder that is taking place
while we observe and document it occurring? 
The governments will blame lack of resources;
UN officials will humbly nod toward the govern-
ments; civil society will say “we did all we could;”
and everybody will go home hoping that next 
time we’ll do better. But for many there will be no
next time. Many will die and suffer while we 
get around to our business. I think today we
should honestly admit our failure, be more realis-
tic, and really mobilize ourselves so by the next
year and onwards we can see at least some
progress in reaching the prevention goals.
RUSSIAN ACTIVIST AT UN: NO PLAN, GREAT INDIFFERENCE, MANY LIVES LOST
The following text is from a speech delivered on June 2, 2005, at a high-level meeting of the UN General
Assembly to review progress toward the UN’s 2001 Declaration of Commitment on HIV/AIDS. The speaker,
Russian activist Anya Sarang, was the coordinator of the Steering Committee of the Central and Eastern
European Harm Reduction Network.
voices from the front
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global HIV prevention strategy in Geneva in
June. The group responsible for the strategy, 
the UNAIDS Programme Coordinating
Board (PCB), split after U.S. officials in 
preliminary meetings insisted that all refer-
ences to needle exchange be removed from
the document. 
In the United States, a coalition of HIV
prevention, drug policy, and human rights
groups—including the Harm Reduction
Coalition, Human Rights Watch, Gay Men’s
Health Crisis, and OSI—issued a sign-on 
letter urging U.S. Global AIDS Coordinator
Randall Tobias not to allow ideology to trump
scientific evidence. Advocates also succeeded
in drawing the attention of lawmakers 
and the U.S. media. Rep. Henry Waxman
(D, CA), the ranking minority member of 
the House Committee on Government
Reform, sent a letter to U.S. Secretary of 
State Condoleezza Rice to emphasize the
dangers of replacing science with ideology 
at UNAIDS. Waxman noted that 17 major
reviews and assessments of needle exchange
had supported the effectiveness of needle
exchange in reducing HIV risk without
encouraging drug use. A June 27 New York
Times editorial referred to U.S. efforts to force
a retreat from needle exchange as “a breath-
takingly dangerous step.”
In Europe, HIV prevention experts
briefed delegations from other member
states to underscore the dangers of 
U.S. attacks on access to sterile needles 
and injection equipment. NGO advocates 
and UN representatives also worked the
hallways at the meeting itself.
In the final discussions at the Geneva
meeting, the United States faced virtually
unanimous opposition. The Netherlands
proposed language about a comprehensive
approach to HIV prevention that included
sterile injection equipment, while Canada
added the importance of “respect for human
rights of drug users.” Delegates from
Europe and Australia, where needle
exchange has contained the HIV epidemic
to a much greater extent than in the United
States, were particularly forceful. Norway
noted that it would be “irresponsible” 
not to base HIV prevention on scientific 
evidence, and Finland suggested that to
remove mention of sterile injection equip-
ment would be “unethical.” Even Senegal, 
a country with few documented cases of
HIV via injection, urged the UN to stick to
the language in favor of harm reduction
adopted by all nations, including the United
States, at the 2001 UN General Assembly
Special Session on HIV/AIDS. 
Confronted by a unified front in Geneva
and growing criticism at home, U.S. offi-
cials limited their objections to a footnote,
recorded in the meeting minutes, saying
that the United States “cannot be expected
to fund activities inconsistent with its own
national laws and policies.”  
The language of the strategy itself,
adopted on June 29, recognized the impor-
tance of the availability of access to sterile
injection equipment and measures to 
protect the human rights of drug users. 
Considered together, the defeat for nee-
dle and syringe programs at the CND and
support for them at the UNAIDS meeting
highlighted the divisions within the UN 
system itself on the issue of harm reduc-
tion. The split between drug control and
HIV prevention in 2005 was often duplicat-
ed at the national level, hampering efforts 
to protect the health of IDUs.
U.S. Needle Exchange Opponent 
Convenes Congressional Attack 
on Harm Reduction 
In the United States, long-time needle
exchange opponent Rep. Mark Souder 
(R, IN) turned his sights on the interna-
tional arena in 2005. As chairman of the
House Committee on Government Reform’s
Subcommittee on Criminal Justice, Drug
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Policy, and Human Resources, Souder con-
vened a hearing to criticize harm reduction
and launched an investigation into U.S.
Agency for International Development
(USAID) support for the approach.
The February hearing entitled “Harm
Reduction or Harm Maintenance?” largely
served as a platform for Souder to assert,
without evidence, that harm reduction 
programs were a Trojan horse for drug
legalization. An array of witnesses called 
by the Republicans argued, among other
things, that harm reduction was morally
suspect and ineffective. In testimony that
astounded and provoked rebuttals from
HIV experts(see page 45), witnesses called 
by Souder, including a Malaysian drug 
treatment provider, testified that needle
exchange violated Hindu and Muslim 
religious beliefs, that there were few 
IDUs in Asia, and that the United States
was “bullying” other countries into adopting
harm reduction. 
Many in the chamber, including those
wearing “clean needles saved my life” 
buttons, perceived the bullying to be in 
the opposite direction. Witnesses called 
by the Democrats, among them drug treat-
ment providers, epidemiologists, and health 
officials, highlighted the overwhelming 
scientific evidence for harm reduction and
presented a sobering picture of the rapidly
growing HIV epidemic in Asia and the 
former Soviet Union. Souder responded 
by accusing several Democratic witnesses 
of favoring drug legalization, and vowed 
to investigate further.
Though the hearing lasted only a day,
efforts to discredit harm reduction may 
not be over. Prior to the hearing, Souder 
had demanded that USAID assemble, on
searchable CD-ROM, all written records,
Police rounding up suspected drug users at a nightclub, Moscow, Russia
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correspondence, and emails mentioning
OSI or its affiliate the Alliance for Open
Society International (AOSI), the International
Harm Reduction Association, the Asian
Harm Reduction Network, and several other
organizations. While USAID strongly defend-
ed its work with IDUs, the demand forced
agency staff and grantees to turn from work
on HIV prevention to exhaustive documenta-
tion. Staff members of AOSI, for example,
were required to duplicate some 25,000 pages
from their Kazakhstan office alone.
WHO Adds Methadone and
Buprenorphine to Essential 
Medicines List
Months of data collection and advocacy by
community groups paid off in June 2005,
when the World Health Organization
(WHO) announced the addition of
methadone and buprenorphine to its 14th
Model (Complementary) List of Essential
Medicines in June 2005. Advocates hoped
the change would end the debate over 
the lifesaving potential of these substitution
treatments and expand their availability 
in the many countries where they are
restricted or banned (see Substitution
Treatment, page 59). 
The change was the culmination of 
nearly two years of advocacy by people living
with HIV, drug users, and their allies. 
In November 2003 a small group met 
with WHO’s director-general, Jong Wook-
Lee, and urged inclusion of methadone 
and buprenorphine on the list of essential 
medicines. This goal was supported by 
an international campaign that included
Human Rights Watch, the European AIDS
Treatment Group, the Central and Eastern
European Harm Reduction Network, 
the Asian Harm Reduction Network, the
International Harm Reduction Association,
OSI, and dozens of local groups. More than
300 organizations and individuals signed 
a letter backing the campaign, and regional
organizations collected and compiled reports
for WHO that summarized evidence of 
the medications’ effectiveness and offered
technical advice on their administration. 
The WHO List of Essential Medicines,
updated every two years since its initial 
publication in 1977, contains 312 medicines
deemed indispensable for cost-effective
medical treatment. The complementary 
category, to which methadone and buprenor-
phine were added, includes medicines that
require some specialized diagnostic and/or
monitoring facilities for their use.
EU Action Plan: Harm Reduction, 
Drug Services, and Alternatives 
to Imprisonment Critical 
Harm reduction won an important source
of support in June, when the Council 
of the European Union (EU) endorsed the
Drugs Action Plan. Drafted in response to
advocacy by EU member states and a call 
by the European Parliament to place greater
emphasis on scientific evidence in the 
formation of a response to illicit drugs, the
plan has three objectives explicitly support-
ing harm reduction:
• Objective 13: “Further develop alter-
natives to imprisonment for drug
abusers and drug services for people
in prisons, with due regard to nation-
al legislation.” Two steps were recom-
mended to realize this goal: “1. Make
effective use of and develop further
alternatives to prison for drug
abusers; and 2. Develop prevention,
treatment and harm reduction servic-
es for people in prison, reintegration
services on release from prison and
methods to monitor/analyze drug use
among prisoners.” 
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• Objective 14: “Prevention of health
risks related to drug use,” to be
achieved by “implementation of the
Council Recommendation on the 
prevention and reduction of health-
related harm associated with drug
dependence.”
• Objective 15: “Availability and access
to harm reduction services,” to be
achieved by “improved access for
addicts to all relevant services and
treatment options designed to reduce
harm, in due regard with national leg-
islation.”
Civil society groups in 2006 will work
to ensure that the EU turns these pledges
into meaningful programs.
UN Task Force: Millennium
Development Goals Require Drug
Policy Reform and Needle Exchange 
A report released in June by a high-profile
UN task force endorsed harm reduction 
as a vital and effective HIV prevention 
strategy. The report, Combating AIDS in 
the Developing World, was prepared for 
the UN Millennium Project’s Task Force 
on HIV/AIDS, Malaria, TB, and Access to
Essential Medicines. 
The task force included HIV prevention
leaders such as International AIDS Society
President Helene Gayle, Kasia Malinowska-
Sempruch of IHRD, and Katherine Hankins
of UNAIDS. Their report identified needle
exchange and opiate substitution treatment
as “the single highest priority in Russia,
Ukraine, much of China and Southeast 
Asia, as well as in large parts of India and
Latin America.” More strikingly, the report
included three recommendations for policy
reform: decriminalizing of syringe and 
needle possession at the national level, 
more active work by the UN to promote the
expansion of harm reduction programs, and
the rescheduling of methadone to a less
restrictive category at the Commission on
Narcotic Drugs. 
The task force was part of a larger 
effort to advance the goals of the UN’s
Millennium Development Project, a cooper-
ative effort begun in 2000 to markedly
improve global human development condi-
tions by 2015. 
voices from the front
“Injecting drug use accounts for 70 to 90 percent of HIV infections in [Central Asia], there-
fore IDUs must be reached to combat the epidemic. Existing needle exchange sites offer an
important opportunity to conduct further interventions with IDUs. Organizations that estab-
lish trust and gain access to the hard-to-reach population can serve as a conduit for other
information, counseling, and referrals . . . . ”
USAID: WORK WITH DRUG USERS IS ESSENTIAL TO COMBATING HIV
Under attack by opponents of harm reduction, USAID confirmed that it does not provide fund-
ing for needle exchange, but strongly defended partnership with needle exchange programs:
Outreach workers for a harm reduction program in Khojand, Tajikistan
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Estimates by UNAIDS suggest that HIV
prevention efforts need to cover 60 percent
of IDUs in order to effectively contain injec-
tion-driven epidemics. Yet no country in 
the former Soviet Union reaches more than
a third of IDUs with needle exchange serv-
ices. Even those counted as “reached” often
have intermittent access to sterile injection
equipment rather than the steady access
needed to stop HIV transmission. 
Harms associated with drug use pro-
ceed as much from restrictive policies as
from a scarcity of sterile needles. Mass
incarceration of drug users, violations of
confidentiality, and frankly discriminatory
health policies such as registration of drug
users are common to many countries 
in the region. Practices that bar drug users
from services or force them into high-risk
environments are found even where people
living with HIV or drug users enjoy legal
guarantees of equal access or fair treatment. 
The following pages focus on
developments in the countries of the
Commonwealth of Independent States
where IDUs are a majority of HIV cases and
where IHRD and local partners worked
most extensively in 2005. 
Over the past decade, the twin epidemics of HIV and inject-
ing drug use have had perhaps their most lethal effects in
countries in Eastern Europe and the former Soviet Union.
Estonia and Ukraine, for example, share the dubious distinc-
tion of having an estimated HIV prevalence of 1.4 percent 
of the population, the highest in Europe. Year after year,
UNAIDS has distinguished the epidemics in the former
Soviet Union as the fastest growing in the world. 
Harm Reduction Developments: 
Central and Eastern Europe and 
the former Soviet Union
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With the exception of Turkmenistan, 
the region’s governments have welcomed
assistance for drug and HIV control from
abroad, including Global Fund grants 
and support from the United Nations 
and donor countries such as the United
States, the United Kingdom, Japan,
Switzerland, Germany, the Netherlands,
and Canada. Portions of Global Fund grants
to Kazakhstan, Kyrgyzstan, Tajikistan, and
Uzbekistan are allocated specifically for 
needle exchange. Additional funds for 
harm reduction have been promised to 
all the Central Asian republics except
Turkmenistan through a $27 million
Regional AIDS Control project launched 
in November 2005 and funded by the 
World Bank. Britain’s Department for
International Development has committed
£6.4 million ($11 million) in assistance over
a four-year period, through 2008, to support
national HIV programs (including an
increase in harm reduction services) 
in Kyrgyzstan, Tajikistan, and Uzbekistan.
USAID has committed $16.5 million for
drug demand reduction, including support
for HIV prevention education, and an 
additional $13 million for a project to build
HIV/AIDS capacity in the region. Other
bilateral funders, including the Japan
International Cooperation Agency and 
the Swiss Agency for Development and
Cooperation, have also supported HIV 
programs in Central Asia. 
While some of these initiatives promise
great increases in harm reduction efforts,
there are wide differences in the number
and kind of restrictions placed on the use 
of these grants. U.S. funds, for example,
cannot be used to purchase needles.
Although substantial international funding
now goes to Central Asian governments
and large international NGOs, significant
questions remain about whether there 
is any mechanism to coordinate activities,
prevent duplication, or ensure that local
NGOs with the strongest ability to reach
IDUs have the funds and freedom neces-
sary to work effectively. The Uzbek govern-
ment’s crackdown on NGOs, for example,
has chilled harm reduction activities in 
that country.
Central Asia
HIV prevalence currently is relatively low in the Central Asian states of Kazakhstan,
Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. However, high rates of injecting
drug use and proximity to Afghanistan, where three-quarters of the world’s opium 
poppies are grown, have placed all five countries on the cusp of major epidemics.
Government responses to the threat have varied considerably, from refusal of interna-
tional assistance (Turkmenistan) to bold attempts to implement and expand a wide
range of harm reduction services, including substitution treatment and needle exchange
in prison (Kyrgyzstan). Strengthening and expanding services remains a priority for 
harm reduction advocates. Substitution treatment, for example, in 2005 was available
only in Kyrgyzstan. 
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Kazakhstan 
A $22 million Global Fund agreement was
at the center of harm reduction develop-
ments in 2005. The grant is meant to enable
needle exchange efforts to reach 35,000
people, about 20 percent of the estimated
174,000 IDUs in the country. At the same
time, drug users and outreach workers
themselves report difficulty in delivering
needed services, particularly through com-
munity-based needle exchange programs
that have yet to receive adequate support.
With needle exchange funds going instead
to government-sponsored AIDS centers, the
government has used Global Fund support
to consolidate control of harm reduction,
shutting out the network of NGOs that had
operated with funding from OSI, USAID,
and other donors. Community-based NGOs
often reach users unable or unwilling to 
go to government-affiliated programs. 
The grant has also not resulted 
in methadone availability. Though the
Kazakhstan government promised in the
Global Fund agreement to deliver methadone
to 100 IDUs by the end of 2005, the
Ministry of Health sought in February to
remove the approach from its grant obliga-
tions. “Having studied the experience of
other countries on introduction of substitu-
tion therapy for drug users,” the Ministry 
of Health wrote to the Global Fund, “[our]
experts have come to the conclusion that 
it is inexpedient to utilize this therapy on
the territory of Kazakhstan.” After negotia-
tions with the Fund, and briefings by inter-
national experts, Kazakhstan scaled back
plans for methadone rather than scrapping
them completely. 
High-level political involvement opened
the door a bit wider for substitution treat-
ment in late 2005. During a September visit
Physician examining the abscess of a harm reduction client, Bishkek, Kyrgyzstan
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to Kazakhstan, former U.S. President Bill
Clinton mentioned to Kazakh President
Nursultan Nazarbayev that methadone 
was both effective and widely used in the
United States. Shortly thereafter, Nazarbayev 
conveyed his enthusiasm to the Ministry of
Health and the Ministry of the Interior,
which are now supportive of pilot projects in
the cities of Pavlodar and Karaganda. Some
75 patients are expected to enroll in 2006. 
Kyrgyzstan
Kyrgyzstan remains the Central Asian
republic with the greatest range of harm
reduction services for IDUs, with both nee-
dle exchange and methadone available
(albeit still in limited quantities), and sever-
al projects that offer both drug-free rehabili-
tation and needle and syringe exchange.
Seven years after Kyrgyzstan struck down 
a law that criminalized drug use, govern-
ment officials, NGOs, and international
experts in late 2005 gathered to review
penalties for drug possession with an eye
toward their revision. Parliament also
approved a new law on HIV/AIDS in June
2005 that guaranteed the confidentiality 
of HIV-related personal data, decreed that
HIV tests must be voluntary, prohibited 
discrimination against people living with
HIV, and guaranteed equal access to 
medical care for HIV-positive individuals. 
Originally funded by IHRD, the Soros
Foundation–Kyrgyzstan, and the United
Nations Development Programme (UNDP),
harm reduction services are now supported
by bilateral aid and by a Global Fund grant.
According to a Global Fund assessment
report from October 2005, a total of 12
“trust points” for needle exchange had been
established at NGOs and government AIDS
centers across the country. While programs
use various approaches, their overall scope
remains limited, reaching about a third 
of IDUs. By November, a combined total 
of nearly 85 individuals were also in
methadone treatment programs at two 
projects, one in the capital city of Bishkek
and the other in the southern city of Osh. 
Kyrgyzstan was also one of the few
resource-constrained countries where nee-
dle exchange was available in prisons in
2005. As of October, 11 prison colonies,
housing about one-third of Kyrgyzstan’s
prisoners, had harm reduction programs.
The Ministry of Justice has agreed to expand
this program to all prisons, as well as to
implement methadone treatment in pris-
ons. The ousting of Kyrgyzstan’s president
in March 2005, the July 2005 elections that
resulted in a victory for his replacement,
Kurmanbek Bakiev, and subsequent power
struggles have brought multiple changes in
government officials and slowed progress
toward these goals.
Tajikistan
Despite severe economic constraints and a
long, mountainous border with Afghanistan,
Tajikistan has a number of programs offer-
ing creative responses to the problems of
HIV and opiate use. In Dushanbe, the NGO
Ran, which combines service provision and
policy analysis, participated in a successful
effort to reduce criminal penalties and 
overcrowding in Tajik prisons. Volunteer, 
a program in the Pamir mountain region
adjoining Afghanistan, offers both needle
exchange and abstinence-based treatment.
The NGO Dina, in the city of Khojand, offers
a comprehensive approach including a drop-
in center for drug users, needle exchange,
drug-free treatment and trainings, and 
support for street children. The Canadian
International Development Agency, IHRD
and the Open Society Institute Assistance
Foundation–Tajikistan (OSIAF), contributed
to the strengthening of the Tajik Harm
Reduction Association in 2005.
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Many harm reduction projects in
Tajikistan expected support from a two-year
Global Fund grant of $2.5 million that
began in January 2005 and focused on 
provision of HIV prevention among IDUs
and other vulnerable populations, including
sex workers and migrants. Delays related 
to disbursement and capacity at the local
level, however, hampered work. As in other
Central Asian republics, the Global Fund
has supported mostly government, rather
than nongovernmental, harm reduction
entities: The grant’s principal recipient,
UNDP, has created a network of 11 harm
reduction programs, many in govern-
ment-run AIDS centers. These programs
were serving an estimated 1,000 clients 
by the end of the year, half the number
reached by seven harm reduction projects
funded primarily by OSIAF. After months
of negotiations, UNDP and OSIAF reached 
an agreement in October 2005 to collabo-
rate more closely to ensure quality and
effectiveness.
While the nation’s drug control agency
officially supports needle exchange, IDUs
continue to report incidents of bribery and
extortion on the part of local police. There 
is no substitution treatment in the country.
Needle exchange in prison, while informally
supported by some government officials, 
is also unavailable.
Uzbekistan
On paper, Uzbekistan has a strong commit-
ment to syringe exchange, endorsing the
creation of 221 “trust points” for needle
exchange at narcological dispensaries and
AIDS centers. Government funding for
these activities, however, has not been forth-
coming: as of December 2005, virtually 
all trust points lacked needles, trained per-
sonnel, or both. Uzbekistan forced the few
NGOs that were providing syringe exchange
with international funding to re-register
with the government in 2004. The govern-
ment also forced the closure of the OSI
HIV and IDUs in Select Central Asian Countries, December 2005
Total Total Estimated IDUs as share of
population registered number total registered
HIV cases of IDUs HIV cases
Kazakhstan 14.8 million 5,440 174,000 76.7%
Kyrgyzstan 5.26 million 807 21,000 77.8%
Tajikistan 6.5 million 506 53,000 70%
Uzbekistan 26.6 million 7,757 87,000 64%*
* “Parenteral” infections, including IDU and other blood-borne cases
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: Population: UN Dept. of Economic and Social Affairs, 2005. IDUs: UNODC HIV/AIDS Unit, September 2005 (midpoint estimates). HIV: Republican AIDS
Centers, December 2005. Data for Turkmenistan unavailable.
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foundation in Uzbekistan that had been a
principal supporter of harm reduction.
Other international NGOs providing sup-
port for harm reduction have faced restric-
tions on their activities, and many local
NGOs have shut their doors. The Andijon
massacre in May 2005, when government
forces killed hundreds of protesters, further
strained relations between the government
and international donors. 
A $4.76 million, two-year Global Fund
grant to Uzbekistan, which began in
December 2004, is supposed to offer sup-
port for harm reduction training, purchase
of needles and syringes, and pilot substitu-
tion treatment. Here, too, the gap between
paper and reality is large. Plans for pilot
substitution treatment, including the
import of limited quantities of methadone
and buprenorphine, were finalized in 2005,
with treatment of 100 patients on buprenor-
phine and 25 on methadone expected to
begin in 2006. Only patients with AIDS
who qualify for ARV will be eligible. 
No Global Fund–supported needles and
syringes had been distributed among IDUs,
according to a report to the Global Fund 
in September. UNDP officials have limited
their engagement with needle exchange 
to trainings and have removed needle
exchange from the list of indicators used 
to gauge success, a move that the few 
NGOs remaining in Uzbekistan are in little
position to protest. 
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* Data as of September 2005
** Data as of December 2004 (more recent data unavailable)
Sources: National/Republican AIDS Centers, WHO (Belarus). Data for Turkmenistan unavailable.
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A total of five needle exchange projects were operating in Georgia as of October 2005.
The Global Fund supported four of the projects, and the Open Society Georgia
Foundation funded the fifth. The projects served a total of about 800 clients, 
and approximately twice that number received legal and social assistance. Substitution
treatment with methadone, due to begin in May 2005 under the terms of a Global 
Fund grant, was delayed following complaints from key Georgian legislators and the
unwillingness of several domestic pharmaceutical companies to import the drug. 
In October, the grant’s principal recipient,
the Georgia Health and Social Projects
Implementation Center, purchased an 
initial methadone supply from an Italian
company, and in December the first eight
patients received treatment at the Institute
of Drug Addiction. Though harm reduction
advocates were engaged in negotiations
with the Ministry of Justice to establish a
pilot needle exchange program in prison in
2005, no concrete steps had been taken by
the end of the year.
Drug policy, too, remains a challenge 
in Georgia, one of the few countries in 
the CIS where the status of drug user is still
criminalized. Support from the Canadian
International Development Agency and IHRD
helped the NGO Alternative Georgia to exam-
ine possibilities for drug policy reform in
2005. In October, the Open Society Georgia
Foundation and the Ministry of Health
joined the NGO to convene an international
conference on the subject.
Georgia, HIV, and IDUs
1) Total population 4.47 million
2) Estimated number of IDUs 12,000
3) Total registered HIV cases 880
4) IDUs as share of total registered HIV cases 64%
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments. 
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) National AIDS Center, December 2005;
4) National AIDS Center, December 2005
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Substitution treatment of any kind for drug
addiction is illegal. HIV has been detected 
in 82 of Russia’s 89 oblasts (regions). Needle
exchange projects operate in only 33 oblasts,
and then often at levels far below the cover-
age needed to achieve lasting results. 
In Moscow, where the largest number of
Russians with HIV resides, there is no 
needle exchange program. Many programs,
begun with grants from donors such as 
OSI, DFID, Médecins du Monde, the Ford
Foundation, and the Open Health Institute,
have been disappointed in their hopes of
support from the government. By 2005, the
national government still offered no finan-
cial backing for needle exchange. Regional
authorities supported programs through in-
kind donations, small grants, or sponsorship
of needle exchange at government clinics,
though NGO programs frequently received
no government funding at all.
Shortfalls in International Funding
Russian harm reduction programs have
looked to international funding to make 
up the gap. The fact of increased foreign
assistance for HIV in Russia, however, has
not meant mechanisms to ensure that those
at greatest risk—IDUs, sex workers, and
sexual partners of drug users—are reached. 
In 2005, for example, more than two years
after signing a World Bank loan for $150
million for TB and AIDS, the government
had yet to deliver substantial support to 
a single harm reduction project. Russia’s
first Global Fund grant, awarded in 2004 
to a consortium of NGOs in a project known
as GLOBUS, supports 23 needle exchange
projects in 10 oblasts, and in 2005 offered
some additional support for harm reduction
projects through grants to the Russian
Harm Reduction Network (RHRN). No
funding for programs outside the 10 oblasts
Russia
With an epidemic concentrated among young IDUs and an economy boosted by 
rising oil prices in 2005, one would expect harm reduction programs in Russia to 
have expanded sharply. In fact, programs to reach IDUs with HIV prevention remained
strikingly limited. 
Russia, HIV, and IDUs
1) Total population 143 million
2) Estimated number of IDUs 1.98 million
3) Total registered HIV cases 333,332
4) IDUs as share of total registered HIV cases 87%*
* Data as of December 2004 (more recent data unavailable)
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Federal Aids Center, December 2005;
4) Federal AIDS Center, December 2004
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is expected for 2006. A second Global Fund
grant, made to a government-controlled
entity, focuses on HIV treatment rather
than prevention. Many bilateral funders
have shifted emphasis to HIV projects that
enjoy greater government approval. 
Overall, a 2005 survey of 38 cities found
that despite the sharp increases in overall
funds for HIV programs from abroad, there
was nearly 30 percent less funding for harm
reduction programs than in 2004. 
Drug Policies that Fuel HIV Infection
In 1998, a tightening of Russian drug laws
made possession of illicit drugs—including
the residue in a used syringe—punishable
by imprisonment. One hundred thousand
Russians were convicted in the first year 
following passage of the new penalties, and
the number of those jailed for drug offenses
increased five-fold between 1997 and 2000.
As in other penal systems (see Prisons, HIV,
and IDUs, page 55), mass incarceration
meant accelerated HIV infections.
The Russian government in 2004
revised the penal code so that possession 
of small amounts of drugs (“less than 10
average single doses”) resulted in an admin-
istrative rather than a criminal offense.
Following the reform, some 32,000 people
were released from prison or had their 
sentences shortened. The Federal Office for
Drug Control and Trafficking had bitterly
opposed the 2004 penal code changes,
claiming that they undermined law and
order. In April 2005, under heavy lobbying
from the Office for Drug Control, State
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Note: UNAIDS recommends 60% coverage for effective HIV prevention among IDUs
Sources: IDU Estimates:  UNODC HIV/AIDS unit, September 2005 (midpoint estimates, data collected 2002-2005); WHO/UNAIDS October 2005 (Ukraine)
Coverage Estimates: Open Society Institute/ Soros Foundation network (Armenia, Azerbaijan, Georgia, Kyrgyzstan, Tajikistan); Russian Harm Reduction Network; 
HIV/AIDS Alliance (Ukraine); GFATM and program reports (Uzbekistan).
Percent of IDUs Reached by Needle/Syringe Exchange Programs
Select CIS Countries, December 2005
less than
1 %
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Duma members considered repeal of key
provisions of the 2004 reforms, including
the removal of “average single dose” termi-
nology from the penal code. The proposed
new law, which had its third and final hear-
ing on December 21, 2005, will set fixed
doses and penalties for mandatory impris-
onment. While these will be determined 
in 2006, AIDS advocates fear that impris-
onment will once again be the penalty for
possession of even small amounts of heroin
or marijuana.
Needle exchange projects also faced 
policy challenges. Since 2003, Russian drug
control authorities have suggested that 
needle exchange programs are in violation 
of laws prohibiting promotion of drug use.
While those claims have been countered 
by expressions of support by the Ministry 
of Health and amendments to the criminal
code that authorize the operations of
“approved” needle exchange programs,
many programs are operating in legal limbo.
A government order clarifying official guide-
lines for syringe exchange, promised in
2005, has yet to be issued. Early drafts 
of this order called for an end to needle
exchange by peer outreach workers, a key
component for successful programs in a
country where many drug users hesitate to
visit central locations for fear of shakedowns
by the police or the addition of their names
to lists kept by government authorities. 
Promising Signs: New Global Fund
Grant and New Commitment from
President Putin
In June 2005, a group of NGOs, including
RHRN and the Russian Community of
People Living with HIV/AIDS, applied for 
a Global Fund grant specifically for support
and expansion of harm reduction projects.
The application sought $10 million over five











Source: Russian Harm Reduction Network, 38-city survey, July 2005.
Decrease of 27% in funding since 2004
$3,000,000
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years to increase the availability of clean
needles and condoms in Russian regions
not covered by the two earlier grants. 
The government-controlled country coordi-
nating mechanism (CCM) for the Global
Fund, which included a high-ranking 
official at the Ministry of Health, the presi-
dent of the Russian Academy of Medical
Sciences, and the head of the Federal AIDS
Center, opposed the application, claiming it
violated protocols and was unnecessary. 
After documenting a pattern of irregular
and potentially discriminatory treatment by
the CCM, however, the NGOs were success-
ful in seeking consideration for Global Fund
support independent of the country coordi-
nating mechanism. In December, RHRN
received word that the grant would be award-
ed so long as the Global Fund could meet 
its own fundraising goals. If awarded, the
grant will mark the single largest financial
contribution for needle exchange in Russian 
history, and a significant achievement for
Russian civil society.
Federal government commitment to
HIV treatment is also increasing. In
September, President Putin announced that
Russia would allocate up to 3 billion rubles
(about $106 million) to fight HIV/AIDS in
2006, an amount 20 times higher than that
provided by the 2005 budget. While declin-
ing to call HIV an “epidemic,” Putin noted
the importance of providing HIV treatment
for all in need, and Ministry of Health 
officials have sought input from NGOs and
UN agencies in determining spending 
priorities. At the close of 2005, however,
Putin was proposing heightened restric-
tions on NGOs working on human rights
and political reform, new restrictions on 
foreign NGOs, and mandatory disclosure 
by Russian organizations and individuals 
of sources of foreign support.
Outreach workers in Volgograd, Russia
voices from the front
HIV drug pricing and regulations. 
Generic ARV was unavailable in Russia in 2005, and medications were purchased
through regional tenders rather than through a centralized mechanism. Though prices
for a year’s supply of first-line combination therapy fell from $12,000 to as low as
$1,200 as a result of Global Fund agreements, medications were still prohibitively
expensive. ARV purchased through government tenders cost as much as $8,000 per
patient per year. 
AIDS care infrastructure.
HIV treatment remained “siloed” in AIDS centers that were separated from the rest of
the Russian health care system, a fact that limited referrals, coordination of care, and
engagement by a range of Russian health professionals. 
Stigma and lack of support for treatment uptake and adherence.
Hostility or indifference to patients with HIV, and lack of efforts to educate patients
about availability of HIV treatment or to help them stick to demanding treatment regi-
mens, meant many missed out on the benefits of treatment.
Separation of HIV and TB services.
TB is the most common killer of people with HIV in Russia, yet TB and AIDS services
in Russia were not integrated in 2005. Many TB and HIV clinics referred patients back
and forth, bouncing them between physicians without providing them critically needed
treatment.
For the full text of the report, go to www.aidstreatmentaccess.org. 
ITPC FINDS GAPS IN TREATMENT PREPAREDNESS IN RUSSIA
The International Treatment Preparedness Coalition (ITPC), a global coalition of HIV treatment
activists, selected Russia as one of eight countries for evaluation in 2005. In November, using an
analysis prepared by people living with HIV in Russia, ITPC issued its report, Missing the Target,
and noted that only about 3,000 of the estimated 50,000 Russians in need of ARV were receiving
treatment. Obstacles noted by the report’s authors included: 
Several projects combine Global Fund
monies, government support, and grants
from private foundations to offer 12-step
(abstinence-based) programs, needle
exchange, HIV treatment education, and
support groups for people who use drugs all
under the same roof. Support from IHRD,
the Canadian International Development
Agency, and the International Renaissance
Foundation, among other funders, helped
Ukrainian advocates integrate HIV preven-
tion organizations into important political
structures, and to press for key policy
reforms in 2005. 
Methadone is not currently available for
substitution treatment, but buprenorphine
is. In September, again with support from
the Global Fund, Ukraine expanded pilot
buprenorphine projects to offer the medica-
tion to people also on ARV treatment in
seven regions. By the end of December
2005, there were 165 people receiving
buprenorphine substitution treatment in
Ukraine, and plans called for scale up 
to 7,000 patients by the end of 2008. The
International HIV/AIDS Alliance and WHO
Ukraine have been key partners in pressing
for quality and availability of the treatment.
Support from IHRD and the
International Renaissance Foundation 
also allowed the launch in September of 
a complementary project to improve ARV
treatment for IDUs by increasing collabora-
tion between providers of harm reduction, 
substitution treatment, and HIV treatment
services. Activists were at the forefront 
of efforts to make this a priority, playing 
a prominent role at a training held in
Nikolayev where providers of ARV,
buprenorphine, and needle exchange
learned about patient case management and
measures to increase adherence to ARV.
ARV treatment became part of the 
presidential agenda in November, when
Ukrainian President Viktor Yushchenko,
his staff, and representatives of the 
All-Ukrainian Network of PLWHA held 
discussions on what activists alleged was 
a nontransparent government ARV pro-
curement process that inflated prices. At
the end of the month, Yushchenko issued a
special executive order calling for the estab-
lishment of a new National Coordination
Council on HIV/AIDS; strengthening
regional AIDS centers; and announcing
that the health minister would sign an
agreement with the Clinton Foundation
HIV/AIDS Initiative. According to that
agreement, the foundation will assist the
Ukrainian government in procuring ARV
and opiate substitution treatments, estab-
lishing a training and mentoring program
for HIV clinicians, and increasing access to
HIV care and treatment programs.
Ukraine
The first country in the former Soviet Union to experience a widespread HIV outbreak,
Ukraine is rightly cited as a regional leader in harm reduction and HIV treatment. 
Laws protect those with HIV from discrimination, the country has a well-established and
highly organized network of people living with HIV, and a Global Fund grant has allowed
syringe exchange programs to grow from a handful supported by private foundations to
more than 250 projects reaching an estimated 70,000 IDUs across the country.
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Restrictive Drug Policy Proposals
Despite a long history of successful AIDS
activism in Ukraine, policy battles are ongo-
ing. In June 2005, advocacy efforts by harm
reduction and PLWHA activists helped
block an attempt by the Ministry of Health’s
Drug Control Committee to reclassify
methadone and place it on a list of drugs
considered “illegal substances for use in any
medical practice,” a move that would have
made future implementation of the treat-
ment extremely difficult. 
After losing the battle on reclassifying
methadone, the Drug Control Committee
proposed changes that would have reduced
the amount of acetylated opium and home-
made preparations of opium that would sub-
ject individuals to possible prison sentences.
Under Ukrainian law, acetylated opium, one
of the most widely used drugs in Ukraine, 
is punishable by imprisonment when the
amount possessed is 0.1 gram or more. 
The proposed reform would have lowered
the amount punishable to 0.002 gram—a
level far below the average single dose used
on the street. The draft also contained 
language that would criminalize the posses-
sion of all parts of poppies, from the whole
plant to specific extracts, regardless of opium
alkaloid content. 
The Drug Control Committee said that
its goal with the resolution was to assist
prosecutors and courts by creating an objec-
tive standard. International and local NGOs
pointed out, however, that strict compliance
with the new standards would mandate
detention of thousands of drug users, thus
further straining the nation’s overcrowded
and unsafe prisons. Those expressing 
concern included Human Rights Watch, 
the International HIV/AIDS Alliance, the
International Renaissance Foundation, 
the International Centre for Policy Studies,
the All-Ukrainian Council for Patient Rights
and Protection, the Ukrainian Harm
Reduction Association, and OSI. 
In July 2005, activists sent an open 
letter to key government officials noting 
that the proposed change “ignores the fact
that over 65 % of the individuals arrested
under illicit drug charges are only found in
possession of drugs, and usually have no
intention to sell them.” In other words, the
advocates noted, “persons most frequently
prosecuted for drug ‘trafficking’ are in fact
merely drug users themselves.”
Ukraine, HIV, and IDUs 
1) Total population 46.5 million
2) Estimated number of IDUs 397,000
3) Total registered HIV cases 86,839
4) IDUs as share of total registered HIV cases 67.8%
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Ukrainian AIDS Center, December 2005;
4) Ukrainian AIDS Center, December 2005
Armenia
In Armenia, where IDUs
accounted for 54 percent of all
registered HIV cases as of
December 2005, fewer than 2
percent of IDUs are reached by
needle exchange services. In
2005, however, officials secured
support from the Global Fund
to build a bold new initiative:
HIV prevention education and
needle exchange in prisons. As
of November 2005, a total of 14
programs offered HIV preven-
tion services to IDUs in prisons,
with three of them offering nee-
dle exchange. Two more prison
needle exchange programs were
expected to be operational by
June 2006. 
Azerbaijan
A two-year, $6.1 million Global
Fund grant received in 2005 
will give harm reduction a major
boost in Azerbaijan, where
IDUs were 49 percent of all 
HIV cases as of December 
and where only 1,750 were being
reached by needle exchange.
Grant targets include reaching
12,500 IDUs with needle
exchange services, and increas-
ing the number of those receiv-
ing methadone from the 80 cur-





activities in Belarus, where 71
percent of cumulative HIV
cases as of September 2005
were among IDUs. Global Fund
support, however, has allowed
expansion of harm reduction
services to an estimated 3,450
IDUs, more than two-thirds of
the end-of-year target of 5,000.
Methadone, though promised
in the Global Fund grant appli-
cation, remains unavailable,
with the Ministry of Health
delaying registration of the
medicine or its endorsement. 
A pilot program for next year
will make the medication avail-
able only for those with AIDS,
as a support for ARV treatment.
Lithuania
Harm reduction came under
sustained attack in 2005 in
Lithuania, where IDUs as of
December comprised 79 percent
of all HIV cases. A campaign
against methadone and the local
Soros foundation that had been
an early supporter of the treat-
ment included calls for investiga-
tion of all Soros-funded entities,
sharp criticism in the media, and
demands by a commission on
drugs in the Lithuanian parlia-
ment to close the country’s
methadone programs entirely.
The health minister, represen-
tatives of the World Health
Organization, and a local coali-
tion of advocates, service
providers, and patients mobi-
lized successfully to correct 
misinformation and emphasize
the harmony of Lithuanian
approaches with international
evidence and the European
Union drugs strategy. At the
close of the year, however, nega-
tive publicity and calls for special
investigations continued.
Moldova
Moldova, where IDUs were 74
percent of all registered HIV
cases in December 2005, was
the first CIS country to imple-
ment needle exchange in pris-
ons. In 2005, it also became 
the first to make methadone
maintenance treatment available
in penal institutions (see Prisons,
HIV, and IDUs, page 55). More
generally, HIV grants totaling
more than $2.4 million from 
the Global Fund, the Swedish
International Development
Agency, and the World Bank
allowed expansion of harm
reduction to vulnerable groups,
including IDUs and sex workers,
through 16 projects nationwide.
Poland
In Poland, where 54 percent of
total HIV cases were among
IDUs as of December, a propos-
al by the Polish Ministry of
Health to decriminalize posses-
sion of drugs for personal use
foundered in 2005 despite sup-
port from leading human rights
and HIV organizations. On the
positive side, new regulations
lowered to 18 the age of those
able to receive methadone, and
authorized NGOs licensed by
the government, rather than
only government clinics, to dis-
pense the medication. Human
rights and HIV advocates hope
the change will allow for expan-
sion of Polish methadone pro-
grams, which for years have
served fewer than 1,000 patients
despite great demand.
EASTERN EUROPE AND THE FORMER SOVIET UNION
country briefs
Worker preparing materials for outreach to drug users, Teheran, Iran
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Even without generalized HIV epidemics,
the populations of countries like China,
India, and Indonesia, home to 40 percent 
of all people in the world, mean that even
relatively low HIV prevalence results in
enormous numbers of people living with
HIV. In India, where UNAIDS estimates
nearly 1 percent adult HIV prevalence and
as many as 8 million total infections, there
are already more people with HIV than in
any other country in the world. 
The fact that HIV infections are fre-
quently concentrated among different
groups in different regions of a single coun-
try make it difficult to define what is meant
by “injection-driven” epidemics. In Burma,
for example, though the majority of offi-
cially registered cases are not among drug
users, an IDU-driven epidemic is exploding
in the eastern and southern regions, 
especially along the border with China and
Thailand. Injecting drug use accounts for
the majority of HIV infections in much 
of northeastern India, notably the states 
of Manipur and Nagaland. Afghanistan,
Cambodia, and Pakistan are all countries
where the majority of HIV infections are
sexually transmitted, but where injection-
driven epidemics are growing rapidly and
must be addressed. 
Harm reduction advances, though
spreading less quickly than HIV, were
marked in Asia in 2005.  As elsewhere in
the report, this section does not represent
anything approaching a comprehensive sur-
vey of harm reduction needs or advances in
Asia in 2005. Instead it offers a snapshot of
some key countries with injection-driven
epidemics where IHRD engaged with inter-
national and local partners during the year.
Harm Reduction Developments: Asia
HIV epidemiologists increasingly refer to what they call the
“second wave” countries of Asia, places where rates of HIV
and the numbers of those infected could lead to AIDS epi-
demics as potentially widespread and devastating as those
experienced in sub-Saharan Africa. 
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While not an absolute majority of HIV cases
in China, IDUs represented an estimated
44 percent of all those infected as of
December 2005—the largest share of a
national epidemic that also included indi-
viduals infected via blood collection prac-
tices or sexual transmission. Nearly 90 per-
cent of all registered cases of HIV among
IDUs were concentrated in seven provinces.
Chinese national guidelines, adopted in
2004, urge the promotion of substitution
therapy and needle exchange as primary
HIV prevention strategies for IDUs. 
Further, the Chinese government has
pledged to nearly double overall spending
on HIV prevention, to some $185 million,
between 2005 and 2007. In July 2005, the
Chinese Center for Disease Control and
Prevention received the first disbursement
of a two-year Global Fund grant totaling $24
million to support HIV prevention and
treatment among IDUs and sex workers in
seven hard-hit provinces. Total Global Fund
support for this effort to reach drug users
and sex workers is expected to be $63 mil-
lion over five years. 
Harm reduction projects have grown
along with funding and commitments from
Beijing. Ninety-one needle exchange proj-
ects were established throughout China as
of November 2005, and the head of the
National Center for AIDS/STD Prevention
and Control (NCAIDS), Wu Zunyou, has 
set a target, with Global Fund support, of 
providing sterile injection equipment to
105,000 IDUs by 2010. Methadone was
being locally manufactured and provided to
more than 6,500 patients in 58 mainte-
nance programs by the end of December
2005, with plans to expand substitution
treatment to 200,000 patients by 2010. 
GFATM assistance will also be used 
to supplement wider government efforts 
to provide ARV, supporting delivery of
China
Those looking for examples of national harm reduction leadership and authoritarian
state control of drug users found both in China in 2005. The five-year plan released by
the Chinese government in June identified the HIV epidemic as a priority public health
concern, further energizing the “four frees and one care” campaign (free antiretroviral
drugs for poor people in urban areas and everyone in rural areas; free voluntary coun-
seling and testing; free counseling and treatment for pregnant women; free schooling
for children orphaned by HIV/AIDS; and economic assistance to families affected by
HIV/AIDS) launched by the government in December 2003. 
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treatment to some 10,000 people with HIV,
including IDUs, by the end of 2007. These
numbers are insufficient to address an 
epidemic the size of China’s, where even by
conservative government estimates at least
650,000 people were thought to be infected
with HIV at the end of 2005. Nonetheless,
the planned scale-up stands in marked con-
trast to other countries where substitution
treatment programs often do not exist and
needle exchange is supported nominally or
not at all by central governments. 
Chinese commitment to quality of
harm reduction programs is less clear.
Some officials have confessed little interest
in the patient-centered aspects of harm
reduction, noting that they favor restricting
future needle exchange primarily to rural
areas. Methadone, seen as a better form 
of crime control, is favored for cities. The
entry criteria for methadone maintenance
programs in 2005 were extremely restric-
tive:  only those who had been through two
institutionalizations in prison-like forced
rehabilitation centers (or one residence in
forced rehabilitation and another in a forced
labor camp) were eligible. Those unable to
produce local residence permits were
denied access. Police, rather than doctors,
often retained final say over whether an
individual could enter methadone treat-
ment. If clinic physicians accepted patients
without complying with these guidelines,
they did so in violation of official policy. 
The emphasis on methadone as a tool 
to increase social control echoed a more
general tension in China between the aims
of the health officials and campaigns
against drug users by the Public Security
Bureau (PSB). Sweeps in which alleged
drug users were sentenced without trial 
to compulsory detoxification facilities were
Anti-drug billboard, Kunming, China
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a routine part of the “People’s War on
Drugs” declared by the PSB in 2005. 
In June, the Beijing PSB urged the creation
of lists of drug users at the community level,
requiring that drug users present them-
selves for mandatory detoxification, and
levying penalties on drug users who failed
to submit. The “People’s War” reportedly
relies on a system of quotas and bonuses to
motivate local police to arrest specific num-
bers of drug users. Hundreds of new police 
have been hired in many provinces, and 
construction of multiple new forced rehabil-
itation centers is underway. In Yunnan
province, for example, the number of beds
at such centers is expected to reach 68,000
by the end of 2008, double the number
available in 2005. Those drug users 
who relapse after forced rehabilitation can
be sent to “re-education through labor”
camps—where inmates perform a two- 
to three-year sentence of work without 
pay for up to 15 hours daily on such tasks 
as assembling dolls or trinkets for the 
burgeoning tourist industry. 
Needle exchange efforts are also seri-
ously constrained by law enforcement.
Reports from northwest China in 2005 
documented clashes occurring between
AIDS activists identified as former drug
users and law enforcement authorities.
Needle exchange outreach workers report
that they have been followed and arrested,
and that police wait near syringe distribu-
tion points to detain drug users. If the
Chinese Narcotics Control Commission is
successful, possession of a syringe may
soon be a crime.  The commission is also
said to be preparing new legislation that will
stiffen penalties for drug consumption as
well as drug possession. 
Even those drug users who gain access
to care may find themselves subjected 
to bizarre and unproven medical interven-
tions. Between 2000 and 2004, Chinese
physicians—basing their approach on simi-
lar operations in Russia—performed brain
surgery on some 500 drug-dependent
patients, drilling holes in their heads and
inserting heated needles that were clamped
in place for days to destroy brain tissue.
Halted temporarily by the Ministry of
Health, this addiction “treatment” was
resumed in China in 2005.
China, HIV, and IDUs
1) Total population 1.32 billion
2) Estimated number of IDUs 1.93 million
3) Total registered HIV cases 141,241
4) IDUs as share of total registered HIV cases 44.3% 
Note: IDUs represent the largest single share of HIV infections in China.
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Ministry of Health, UNAIDS and WHO,
December 2005; 4) Ministry of Health, UNAIDS and WHO, December 2005
voices from the front
A Danish musician from the 1960s wrote a song
about Kathmandu: “The streets are made of rub-
ber—take off your shoes and walk on them.” In
present day Kathmandu, if you take off your
shoes there is a chance that you will get pricked
by a needle. Over 70 percent of drug users living
in this historic city are infected with HIV.
However, this neither rings an alarm for the gov-
ernment nor for the development partners work-
ing in Nepal. Our government is silent because
it is in denial. The development partners are
silent because Kathmandu is neither strategical-
ly nor politically important for them. For exam-
ple, the Global Fund has overtly ignored the
challenges it is facing in this country. Some time
back a former board member of the fund wrote
to me, “Unfortunately Nepal is not a priority 
for the fund.”
Tourists traveling to Nepal in the early 1960s
wondered if Kathmandu had more temples than
houses where people lived. If so, then it obvious-
ly had more gods and goddesses than people.
Maybe it was true [then] but not anymore. As far
as gods and goddesses, though, in the past few
years I have turned into one myself. And it is
really a difficult job.
So what are my responsibilities as a god? One
of my major roles is to decide who lives and who
dies. In the Hindu religion we believe in reincar-
nation, so it is easier for me to decide who
should die now and be reborn and who should
continue with their current life. This year I have
already permitted a few people to die. Can you
believe it?
Recently a guy came to me and asked me for
help. He had TB and had been living with HIV for
the past several years. He was poor and had no
one to look after him. He was weak and weary. 
I decided to help him out since I had some funds
for his basic checkups, for some ARV drugs, if 
he needed them, and TB treatment was available
for free. I welcomed him to my hospice. He was
immediately put on anti-TB treatment and his
CD4 was checked. He needed ARVs too. His CD4
count was less than 50.
Now the real challenges began. We only had 
a nevirapine combination (AZT, 3TC and nevirap-
ine) available to us. We had to find money to put
him on an efavirenz combination since he was
also on TB medication. Then he showed signs 
of anemia and we changed his regimen again.
Then he started complaining about losing his
eyesight. The doctors suggested that it could 
be CMV or it could be toxoplasmosis. And then 
it was time for me to decide if he was to live 
or be left to die. And he is not the only person 
I am looking after.
I cannot afford to keep him alive.
This is not the world we wanted for people liv-
ing with HIV. This is not what activists around the
globe are fighting for. AIDS has divided this world
in two—one for the rich, where clinical trials are
underway for a new generation of improved ARV
drugs, and one for the poor where people still
have to live at the mercy of gods like me.
PLAYING GOD IN KATHMANDU
In 1991, Nepal was the first developing country where an NGO established a needle exchange program.
Although IDUs made up 21 percent of officially registered cases in 2005, prevalence rates among IDUs 
in some parts of the country were are as high as 70 percent. Rajiv Kafle, coordinator of the Kathmandu 
HIV advocacy and support organization Navairan Plus, posted the following essay to a listserv in spring 2005.
It is reprinted with the author’s permission.
38 Harm Reduction Developments 2005
Methadone, for example, is not generally
available in Indonesia, but nearly 400
patients receive the substitution treatment
through special pilot projects in Jakarta and
Bali co-sponsored by the World Health
Organization (WHO) and the Ministry 
of Health. Indonesian prison authorities 
in 2005 also piloted methadone mainte-
nance, opening pilot programs in Bali and
Jakarta, with 15 people receiving substitu-
tion treatment in Bali’s Kerobokan prison 
by December. A small number of physicians
in different regions have been trained and
certified to prescribe buprenorphine as a
substitution treatment. 
Needle exchange programs operate in a
similarly small-scale and legally ambiguous
fashion, with officials across Indonesia’s
6,000 inhabited islands differing on
whether federal law permits or prohibits 
the approach. In Bali, for example, where
the governor is supportive, several NGOs
offer needle and syringe exchange and 
support for IDUs with HIV, as well as pro-
grams for drug users who express interest
in modifying, reducing, or eliminating their
Indonesia
The world’s most populous Muslim nation, Indonesia is famous for its rigid anti-drug
laws, and has made headlines for threats to execute foreign visitors caught with drugs
in their luggage. Yet the government of President Susilo Bambang Yudhoyono, who took
office in October 2004, surprised observers in 2005 by his public support for new strate-
gies to prevent HIV among IDUs. 
Indonesia, HIV, and IDUs
1) Total population 222 million
2) Estimated number of IDUs 580,000
3) Total registered HIV cases 4168
4) IDUs as share of total registered HIV cases 44.1%
Note: IDUs represent the largest single share of HIV infections in Indonesia.
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) World Bank, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Ministry of Health, September 2005; 
4) Ministry of Health, September 2005
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drug use. One NGO on that island, Yaysan
Mata Hati, also works closely with staff at
Kerobokan prison to develop peer education
and pre-release programs. Another Bali
NGO, Yakeba, runs programs for those
recently released.
Elsewhere in Indonesia, syringe pro-
grams operate in quasi-underground fash-
ion, with needle exchange a rarely discussed
component of other outreach efforts to
IDUs. By December 2005, some 20 needle
exchange programs were operating in five
different Indonesian provinces, with several
of them housed in community public health
centers known as puskesmas. Estimates of
numbers of those served by such efforts 
are impossible to obtain. AusAID is the only
donor currently supporting both needle
exchange and methadone provision. 
The limited scope and longstanding
pilot status of both substitution treatment
and needle exchange mean that harm
reduction is available to only a fraction of
Indonesian IDUs. In the past two years, 
an estimated 80 percent of new HIV cases
in the country have been the result of con-
taminated needles, making the epidemic
one of the most concentrated among 
IDUs outside the former Soviet Union. The 
epidemic is particularly dire in prisons,
where Indonesian authorities operate spe-
cial facilities for narcotics-related crimes,
and in which WHO estimates that as many
as 25 percent of inmates are HIV-infected.
Harm reduction activist (left) and her team, Jakarta, Indonesia
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The first substitution treatment program in
Iran was initiated by an NGO, Persepolis, 
in 1999 in the city of Marvdasht. Using
buprenorphine, Persepolis provided treat-
ment to more than 3,000 people dependent
on heroin. In 2005, the NGO operated three
drop-in centers in Teheran that offered com-
munity-based methadone maintenance
treatment along with peer counseling, nee-
dle exchange, outreach, food, showers, and
support for those on ARV. In December
2005, approximately 1,500 people received
methadone from clinics run by Persepolis,
the Iranian National Center for Addiction
Studies and others, and 2,100 more patients
were receiving substitution treatment in
prison clinics. Demand still far outstripped
supply: Persepolis alone reported a waiting
list of as many as 1,500 Iranians hoping for
substitution treatment.
Overall levels of needle exchange were
difficult to estimate in 2005. Some services
were provided by the “triangular clinics”
where the Ministry of Health, NGOs, and
Iran
The Iranian government has demonstrated more openness to harm reduction than most
countries in Asia or the former Soviet Union. As in many Asian countries, those convict-
ed of drug trafficking in Iran face stiff sentences, including flogging, imprisonment, or
execution.  Iranian officials, however, have separated efforts to control drug trafficking
from those to help drug users, speaking out in favor of harm reduction at international
meetings and providing financial support for substitution treatment and needle
exchange.
Iran, HIV, and IDUs
1) Total population 69.5 million
2) Estimated number of IDUs 206,000
3) Total registered HIV cases 12,556
4) IDUs as share of total registered HIV cases 62.3%
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Ministry of Health, January 2006; 
4) Ministry of Health, January 2006
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En route to outreach, Teheran, Iran
community-based groups collaborate to offer
health services to IDUs and PLWHA. The
clinics generally provided condoms, bleach
to sterilize needles, and ARV and TB treat-
ment for those in need—although their loca-
tions in city hospitals or health centers made
them difficult to access for some drug users
and an unlikely site for exchange of large
numbers of syringes. Approximately 70 “tri-
angular clinics” were in operation in Iranian
communities in 2005, with an additional 
50 clinics in prisons offering methadone
maintenance and health services. 
Prison harm reduction services are a
particularly high priority, since an estimated
half of the nation’s 130,000 prisoners have
been charged with drug offenses, one-fifth
are estimated to be IDUs, and perhaps a
quarter of incarcerated IDUs are HIV-posi-
tive. Two pilot needle exchange programs
began in Iranian prisons in 2005, though
needles will not actually be provided to pris-
oners until 2006. 
While harm reduction services were
once regarded as illegal, officials have
explicitly indicated that the programs bene-
fit society and should not be impeded. In
January 2005, the head of the Iranian judi-
ciary, Ayatollah Seyed Mahmood Hashemi
Sharoudi, issued an executive order to
“remind judges at all courts of justice and
prosecutors’ offices” that provision of sterile
injection equipment and methadone main-
tenance treatment are “motivated by. . . pro-
tecting society from the spread of deadly
contagious illnesses.” The order concluded
voices from the front
HEAD OF IRANIAN JUDICIARY URGES PROSECUTORS 
NOT TO IMPEDE HARM REDUCTION
January 24, 2005
Ref: 1-83-14434
ISLAMIC REPUBLIC OF IRAN
Judicial Branch
Executive Order to All Judicial Authorities Nationwide
The legal obligations of the Ministry of Health and Medical Education include the
implementation of programs necessary for the prevention of transmission of commu-
nicable diseases that promote harm reduction and the maintenance of public health
and well-being of society. . . . Interventions that have been supported by the Ministry 
of Health and Medical Education include provision of needles, syringes, and other 
materials used by drug addicts and AIDS patients, as well as methadone maintenance
treatment programs as a means of combating HIV and hepatitis infections among
those addicted to drugs. 
According to the Ministry, some judicial authorities have regarded such interventions
as the abetting of crime, and so subject to punitive action. . . . [This attitude is] uninten-
tionally impeding the implementation of health and treatment programs aimed at 
preventing and combating the transmission of dangerous contagious diseases.
Therefore, this is to remind judges at all courts of justice and prosecutors’ offices
throughout the country that since a major element of abetting crime is verification
of malicious intent, the said interventions are clearly void of such malicious intent
and rather motivated by the will to fulfill the mission of protecting society from 
the spread of deadly contagious diseases such as AIDS and hepatitis. Judicial
authorities should…not unfairly characterize service providers as facilitating crimi-
nal abuse of narcotics, and must not impede the implementation of such needed
and fruitful programs.
Ayatollah Seyed Mahmood Hashemi Sharoudi
Head of the Judiciary
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IDUs as Percent of Total Registered HIV Cases
Select Asian Countries, 2005
* Data as of December 2004 (more recent data unavailable)
Note: IDUs represent largest share of HIV cases of known origin in both China and Indonesia. 
Sources: China Ministry of Health / UNAIDS / WHO, January 2006; Indonesia Ministry of Health, September 2005; Iran Ministry of Health, January 2006; 


















with the hope that law enforcement would
not impede the work of these “needed and
fruitful programs.” (see page 42)
Mahmoud Ahmadinejad, the surprise
victor in Iran’s June 2005 presidential elec-
tions, took office in August. Despite a repu-
tation for social conservatism, he also
brings a history of support for harm reduc-
tion, having issued an order authorizing 40
methadone programs as mayor of Teheran.
Although that order was not fulfilled, 
the Ahmadinejad government has shown
no signs of retreat from public support 
for harm reduction. In September 2005, 
the Ministry of Health asked the World
Health Organization (WHO) to review exist-
ing harm reduction efforts among IDUs
nationwide, and to provide recommenda-
tions for further expansion of Iranian harm
reduction efforts. On December 1, World
AIDS Day, Deputy Health Minister
Moayyed Alavian announced that the 
ministry was determined to sharply scale up
activities to ensure that 50 percent of Iran’s
IDUs, rather than the 5 percent currently
reached, would have access to harm reduc-
tion services. Emphasizing collaboration
with civil society, Alavian noted that the
prevalence of HIV and hepatitis C among
IDUs made it clear that all available
resources must be focused on cost-effective,
evidence-based interventions that had been
shown to slow transmission of blood-borne
illnesses in other parts of the world.
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Malaysia, HIV, and IDUs 
1) Total population 25.3 million
2) Estimated number of IDUs 195,000
3) Total registered HIV cases 65,000*
4) IDUs as share of total registered HIV cases 75%*
* Data as of December 2004 (more recent data unavailable)
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments.
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Malaysia Medical Association, 
December 2004; 4) Malaysia Medical Association, December 2004
Nonetheless, increases in HIV among IDUs
in 2005 moved Malaysian authorities to
reexamine their approach, and brought
striking new interest in harm reduction.
While data were not available for 2005,
IDUs represented 75 percent of cumulative
HIV cases at the end of the previous year. 
In September 2005, Malaysia’s health min-
ister, Chua Soi Lek, announced that the 
government would support two pilot harm
reduction initiatives. The first, which began
in October 2005, will provide methadone to
more than 1,000 drug users for a six-month
period. The government allocated nearly
$650,000 to a total of 16 clinics, each of
which will treat up to 120 clients, and
agreed to subsidize treatment for those who
could not afford it.
The second project, slated to begin in
January 2006, will fund programs to 
provide clean needles and condoms to IDUs
in three cities. Chua said that the project
would be monitored and evaluated by a task
force comprising officials from his ministry,
the National Drug Agency, and the police. 
If a favorable evaluation results after the 
12-month pilot stage, the government will
expand the project nationwide. 
Plans for harm reduction have proven
contentious. Some religious and political
leaders have lobbied instead for further
strengthening of Malaysia’s drug laws, with 
one member of parliament suggesting in
March 2005 that a useful deterrent would 
be public beheadings of drug users and 
Malaysia
Malaysia, where the 1952 Dangerous Drugs Act has been repeatedly amended to
increase penalties for illicit drug use, is famous for a zero-tolerance approach to illicit
drugs. The law allows police to detain those suspected of drug use for up to two weeks,
to force them to submit to urine testing, and to send those who have used illicit sub-
stances to compulsory treatment camps. Repeat offenders found in possession of any
amount of illicit substance face mandatory flogging and imprisonment. Possession of 15
grams (1/2 an ounce) of heroin or 200 grams (seven ounces) of marijuana is punishable
by death, and some 230 people have been hanged under this statute since 1975. 
In January 2005, authorities announced that possession of a syringe would also be 
punishable by incarceration.
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voices from the front
IS HARM REDUCTION “UN-MUSLIM?” A MALAYSIAN INFECTIOUS DISEASE
EXPERT OFFERS RELIGIOUS GROUNDS FOR ACTION
In February 2005, a Malaysian drug treatment provider told a subcommittee of the U.S. Congress
that harm reduction was “un-Muslim” (see page 13). The following are excerpts from a written
rebuttal provided by Adeeba Kamarulzaman, chief of the infectious diseases unit at the University 
of Malaya Medical Center. 
As an HIV/AIDS physician practicing in
Malaysia, and a Muslim, I wish to clarify some of
the statements . . . with respect to the problem of
drug use in the region and Islam’s perspective
on these issues. In many parts of Asia, unsafe
injecting practices have been the primary risks
driving the explosive HIV/AIDS epidemic . . . .
Drugs and indeed alcohol are haram (forbidden)
for all Muslims, as Islam forbids any action that
would result in harm or destruction. However,
beyond the simple haram and halal (permitted)
of substances such as drugs and alcohol lies the
fundamental objective of Islamic divine laws,
which is the protection and preservation of faith,
life, intellect, progeny, and wealth. . . .
Harm reduction can therefore be accepted 
as a necessity in order to preserve [these aspects
of life] that are threatened by the twin epidemics
of drug use and HIV/AIDS. In Islam, life and
good health must be protected and promoted in
all circumstances, and this includes prevention
and treatment of any illness and disease.
The principle of injury in Islam (darar) asserts
that no one should be hurt or cause hurt to
others (la darara wa la dirar) . . . The law requires
that any injury should be mitigated to the extent
possible. A legal dictum in Islam gives the 
provision that “a lesser harm may be tolerated 
in order to eliminate a greater harm. . . . ” 
Harm reduction programs, for which there 
is compelling scientific evidence . . . are therefore
not against Islamic principles . . . . It is of greater
harm for Muslims to allow more injecting drug
users and their family members to be infected
with HIV/AIDS than it is for them to allow a
harm reduction program to take place.
traffickers. A leading senior cleric, Hausaani
Zakaria, strongly recommended in May 2005
that “HIV-infected persons should be held
confined on an isolated and remote island and
not endanger society with their infection.”
By contrast, a number of influential
Malaysians have argued that current drug
laws have failed to deter drug use and are
inadequate to address HIV. In June 2005,
Marina Mahathir, then head of the Malaysian
AIDS Council and daughter of a former
prime minister, called for reform of the
Dangerous Drugs Act. She was particularly
critical of provisions allowing criminal
charges to be filed against an individual in
possession of a syringe for any reason. Such
policies, she said, limit the ability of IDUs 
to obtain clean needles and syringes and
greatly increase their risk of HIV. Mahathir
strongly supported the methadone and 
needle exchange pilot programs. So did
Adeeba Kamarulzaman, the head of the
Infectious Diseases Unit at the University 
of Malaya (see box above). 
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Since passage of the strategy, the govern-
ment has reaffirmed and further articulated
its commitment. In June 2005, Pham Manh
Hung, deputy director of the Party Central
Committee’s Commission for Science and
Education, announced at a Hanoi press 
conference that methadone would be made
available for drug-dependent individuals
across the country. Pham’s comments were
reinforced in October when government
officials and the World Health Organization
issued a joint statement emphasizing that
substitution treatment for drug users would
be a vital part of the country’s response 
to HIV in the future. In July 2005, the
Ministry of Health submitted a draft law 
to a committee of the National Assembly
that included provisions to protect the
human rights of people with HIV; strength-
en HIV-related confidentiality; expand HIV
treatment, care, and support; and hasten 
the implementation of HIV prevention,
including needle and syringe programs and
methadone maintenance. The National
Assembly is expected to approve the law,
which is scheduled for a vote in May 2006.
To a limited extent, Vietnamese rhetoric
has been matched by action. Some 30 nee-
dle exchange programs operate in the coun-
try, many using peer outreach workers. 
A cross-border program offering direct 
distribution and pharmacy vouchers for
needles and syringes, funded by the Ford
Foundation (for services) and the U.S.
National Institute on Drug Abuse (for
research and evaluation) has operated since
2001 in northern Vietnam and southern
China, offering access to about 25,000 
needles/syringes per month. In many proj-
ect sites, HIV infection rates have declined.
An AusAID-funded project offers harm
reduction training and education to public
security and prison personnel in Vietnam,
Burma, and China, though it provides 
no condoms or needles in Vietnam.
Vietnamese pharmacies sell syringes very
cheaply— for about one-twentieth  the price
of a shot of a heroin—though this does not
mean that drug users are willing to risk 
buying them or have enough money to do
so after purchasing drugs. Most pharmacies
are also closed during the hours of greatest
IDU activity.
As in other Asian countries, harm reduc-
tion programs do not reach anywhere near
all those in need, and government support
Vietnam
The Vietnamese government’s HIV prevention strategy for 2005–2010 explicitly supports
harm reduction, including needle exchange and methadone maintenance, as important
parts of HIV prevention for IDUs. The strategy also contains a commitment to include
IDUs in all HIV prevention and care services. 
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Vietnam, HIV, and IDUs
1) Total population 84 million
2) Estimated number of IDUs 113,000
3) Total registered HIV cases 103,000
4) IDUs as share of total registered HIV cases 52%
Estimates of HIV cases and number of IDUs vary sharply, and are frequently higher than those provided by national governments. 
Sources: 1) UN Dept. of Economic and Social Affairs, 2005; 2) UNODC HIV/AIDS Unit, September 2005 (midpoint estimate); 3) Vietnamese Ministry of Health, November
2005; 4) Ministry of Health/National Institute of Hygiene and Epidemiology, 2005
for harm reduction is counterbalanced 
by punitive campaigns that cast drugs and
drug users as “social evils.”  While it is legal
to buy or possess syringes, it is illegal to use
them to inject illicit drugs, and IDUs are
reluctant to carry needles for fear of arrest.
Vietnamese law enforcement conducts peri-
odic crackdowns that result in many IDUs
being sent to rehabilitation centers (“06 cen-
ters”) that human rights groups charge are
more like forced labor camps and offer little
or nothing in the way of real substance
abuse treatment.  UNAIDS estimates that
more than 55,000 drug users are currently
held in such centers, where they are kept for
years without clear terms for their release
and without provisions for treating the many
who are HIV positive. Terms of detention are
longest in the south, where approximately
35,000 were held in Ho Chi Minh City alone
in 2005. Researchers estimate that relapse
rates upon release from these centers are in
excess of 90 percent, making transitional
programs to prevent relapse and HIV trans-
mission sorely needed.
A 1997 law prescribes the death penalty
for anyone found in possession of 100 grams
(3.5 ounces) of heroin or five kilograms 
(11 pounds) of opium. According to Amnesty
International, half of the 88 people executed
in Vietnam in 2004—a year in which the
country ranked third, behind China and 
Iran, in number of executions carried out—
were convicted of drug offenses.
The selection of Vietnam as a focus
country for the U.S. President’s Emergency
Plan for AIDS Relief (PEPFAR)—the only
PEPFAR country in which injection drives
the HIV epidemic—has not increased the
accessibility of harm reduction. By U.S. 
policy, none of the $34 million awarded to
Vietnam can be used for needles or syringes.
The PEPFAR program includes plans for
substitution treatment and the Ministry of
Health has authorized a pilot program in
Hai Phong, though the commitment has yet
to translate into needed services. 
PEPFAR monies were used primarily to
support HIV treatment in 2005, with the
goal of reaching 1,500 patients with ARV
and expanding a pilot project to curb moth-
er-to-child HIV transmission. In the future, 
it will be essential for the program to reach
detainees in prisons and drug rehabilitation
centers, where neither needle exchange or
methadone is now available. 
Protest by Thai Drug Users Network, Bangkok, Thailand
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Estimates of total numbers reached by 
harm reduction services are unreliable.
Many programs lack the resources or staff 
to respond to national or international 
surveys. Providers may use different defini-
tions of “client,” “treatment,” or those 
they count as having been “reached.”
Interruptions in funding or supplies of
syringes or medications, and crackdowns
on IDUs or those who serve them, can inter-
rupt services or discourage attendance.
More broadly, the number of registered HIV
infections among IDUs is often a function
of testing sweeps and police roundups
rather than the result of careful assessment.
Nonetheless, available data is clear. 
In key areas of HIV prevention and treat-
ment, such as opiate substitution treatment
or harm reduction programs for prisoners,
the need for services far exceeds supply.
Illicit drugs are widely available. Services 
to protect drug users are not.
The following overviews report on a
number of areas central to IHRD’s harm
reduction approach.
Harm Reduction Overviews
At a special session of the United Nations General Assembly
in 2001, member states committed themselves to action on
HIV, including expansion of harm reduction and availability
of sterile injection equipment.  At the close of 2005, despite
evidence of harm reduction’s effectiveness, much progress
was still needed.  Strikingly, none of the developing/transi-
tional countries where IDUs are the majority of HIV infections
has taken harm reduction programs to national scale.
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Despite social stigma, institutionalized 
discrimination, harassment from law
enforcement, and lack of economic
resources, a growing number of organiza-
tions are advocating for the needs of drug
users and PLWHA. The Collaborative 
Fund for HIV Treatment Preparedness, 
the American Jewish World Service, the 
Levi Strauss Foundation, the Mainline
Foundation, the Australian Federation of
AIDS Organizations, IHRD, and others
have provided financial and technical
assistance to help create organizations run 
by and for current and former drug 
users. These drug user groups also work to
support each other.
Thailand
The Thai Drug Users Network (TDN) won
international attention for its criticisms 
of the  government’s 2003 war on drugs 
that included use of blacklists to arrest or
intern more than 50,000 alleged drug
users; forced testing at nightclubs and bars; 
and the killing of nearly 3,000 Thais in
gangland-style executions without trial.
Galvanized by the brutality of the govern-
ment and the fact that the Thai minister 
of health was ignoring an HIV epidemic
that had infected one in two Thai injectors
since the late 1980s, TDN applied for and
won a $1.3 million Global Fund grant—the
first ever awarded to a drug-user organiza-
tion—to support involvement of drug users
in the planning and implementation of
harm reduction services and policy advocacy. 
The battle to secure access to treatment
in Thailand, whether to HIV services or to
participation in clinical trials, is far from
over. In an October 2005 meeting, for exam-
ple, a doctor who dispenses methadone at a
major Bangkok hospital described working
with active drug users as “trying to corral
dogs into their cage.” The comparison, not
lost on TDN members present, prompted
one to respond, “Of course, if that’s how you
perceive us, you will never understand us, as
dogs and people speak a different language.” 
Bulgaria
In Sofia, the group Hope organized
methadone patients, current and former
drug users, and their allies to monitor 
the quality of drug treatment and medical
services and to document abuses. Hope 
has also pressed for legal reform in the wake
of a Bulgarian law passed in April 2004 that
re-criminalized possession of any amount
Community Mobilization: Organizations 
of Drug Users and People with HIV
One of the enduring lessons of the HIV epidemic is that the expertise and engagement
of those affected is critical to effective treatment and prevention. In countries with injec-
tion-driven epidemics, where those infected and affected by HIV are often “hidden” pop-
ulations—drug users, sex workers, prisoners, and migrants—enabling community
engagement means confronting particular challenges. People who use drugs are more
easily engaged by peers than by officials who frequently seek to control them rather
than to offer assistance. Even in international meetings and national initiatives where
greater involvement with people living with HIV is a priority, the voices of drug users
are often silenced.
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of illicit drugs, imposing a minimum penal-
ty of three years in prison. The new law also
added a “conspiracy” charge that imposed
prison sentences of 10 to 20 years for drug
crimes committed by multiple people, a pro-
viso that meant that three teenagers sharing
a marijuana cigarette might face up to 20
years’ imprisonment. Calling attention to
the severity of the punishment and the ways
in which incarceration would fuel HIV,
Hope helped organize public demonstra-
tions that drew more than 2,000 protesters,
and collaborated with the Open Society
Institute–Sofia on a project to monitor and
publicize the impact of the new law. On
June 26, 2005, the UN’s International Day
Against Drug Abuse and Illicit Drug
Trafficking, Hope organized more than 
300 drug users to sign a petition presented
to the media requesting political asylum 
in Iran. There, they noted, methadone and
syringe exchange were more freely available.
Ukraine
In Kherson, the first patients receiving
buprenorphine organized a group, Awake!,
to raise community awareness and rally
support for the program. The Kherson 
program, one of two pilot buprenorphine
projects operating in summer 2005, expe-
rienced a crisis after supply problems
forced doctors to sharply cut doses 
to patients. The program sponsor, UNDP,
announced that it would have no medicine
left by September. Awake! passed out
leaflets in the street; joined with drug treat-
ment physicians, AIDS advocates, and par-
ents of drug users to publicize the benefits
of substitution treatment; and appeared on
roundtables and in the media urging that
the program be continued. The European 
AIDS Treatment Group, the International
HIV/AIDS Alliance, and IHRD joined the
fight, and the push succeeded in ensuring
that the Kherson program was among the
seven supported by Ukraine’s Global Fund
grant. Awake! members and other patients
of the program experienced no treatment
interruption. Dozens more opiate-depend-
ent people and their family members have
contacted Awake! to learn more about treat-
ment with buprenorphine.
Russia
FrontAIDS—the network of activists that
made headlines by conducting civil disobedi-
ence protests in Kaliningrad and elsewhere
in 2004—continued to use direct action to
draw attention to the lack of affordable HIV
treatment, government failure to provide
substitution treatment, and discrimination
against people with HIV in Russia. In May,
some 35 activists from regions including 
St. Petersburg and Irkutsk, Siberia, many
traveling across the country at their expense,
gathered to form a “Bridge of Shame,”
chaining themselves in front of the Ministry
of Health in Moscow to protest the lack 
of ARV availability in the country. Among
their demands were the registration and 
production of generic ARV in Russia; 
adoption of WHO HIV treatment and care
protocols, including access to substitution
treatment; and government commitment to
an emergency meeting regarding provision
of HIV treatment. 
China
In the southwest of the country, near 
the Burmese border, the Ruili ARV
Treatment, Education and Self-Support
Group Construction Project was established
in 2005. The project created the first group
for people with HIV in the city of Ruili,
where the majority of those living with HIV
are IDUs and ethnic minorities. The group’s
objectives include increased treatment 
education and adherence for the small
number receiving ARV, activities to increase
demand for treatment, and outreach in drug
rehabilitation centers and labor camps. 
voices from the front
Consulting with people who use drugs: Do’s and Don’ts
Do Don’t
Invite several of us Invite just one of us
Invite a user group to select representatives Always hand-pick the same user you know 
and are comfortable with
Invite an active user Only invite former users
Invite former users in addition to active users Invite them instead of inviting active users
Hold a meeting or consultation in a  Hold it in a government building
low-key setting or in a setting where 
users already hang out
Provide an honorarium—contrary to most   Assume that we don’t need an honorarium 
people who attend your meetings, we are not  or would just spend it on drugs (or that it 
paid to attend by our jobs, but still need to wouldn’t be justified even if we did)
look after our needs
Guarantee confidentiality Identify users and what they said in the 
proceedings of the meeting
Show flexibility with meeting times Hold a meeting at 9 a.m., or on the day when 
welfare checks are issued
Assign us a support person or provide Run your committee or board meetings 
training if you ask us to be on a committee  without acknowledging that it may be the
or board first time for us to be on a committee or 
board
For the full text of the recommendations and the CHALN report, see www.aidslaw.ca.
CONSULTING WITH PEOPLE WHO USE DRUGS: RECOMMENDATIONS FOR
EFFECTIVE ENGAGEMENT
In 2005, The Canadian HIV/AIDS Legal Network (CHALN) consulted with drug user organizations in
Canada and internationally to frame key issues around inclusion of people who use drugs in policy and pro-
gram work. In December, CHALN issued Nothing About Us Without Us, an examination of the public
health, ethical and human rights imperatives of greater and more meaningful involvement of people who
use illegal drugs. An excerpt of drug users’ suggestions for effective collaboration is below.
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Treatment disparities are due in part to
social and economic isolation, including
fear by drug users that authorities may
harass or detain them if they seek HIV test-
ing or treatment. Yet medical providers in
countries with injection-driven epidemics
have often denied services to IDUs who
have sought ARV, claiming that drug users
are unproductive and undeserving, or that
their chaotic lifestyles make them unable 
to adhere to treatment. These claims have
been made even where drug users are sub-
ject to more extensive controls than others
with HIV, and despite studies showing that
drug users, when offered appropriate 
supports, enjoy the same benefits from and
adherence to ARV as other people with HIV. 
• In China, for example, a 2004 report
by Human Rights Watch found that
drug users detained in compulsory
detoxification centers were tested for
HIV but not told the results or offered
treatment. 
• In Russia, where IDUs represented
90 percent of cumulative HIV infec-
tions in 2002, a report by the Central
and Eastern European Harm
Reduction Network (CEEHRN) noted
that none of those in Moscow or 
St. Petersburg on ARV were IDUs.  
A Human Rights Watch report from
2004 found that active IDUs were 
still excluded from ARV in St.
Petersburg. The chief physician 
of the City Health Committee, 
Elena Vinogradova, told researchers: 
“We know who can be trusted and
who can not.”
• In Malaysia, a 2003 report commis-
sioned by the HIV/AIDS Task Force
of the Millennium Development
Project noted that prisons and com-
pulsory treatment centers tested
detainees for HIV, segregated those
who tested positive, but offered them
no ARV. 
• In Vietnam, a 2001 assessment by 
the Centre for Harm Reduction at 
the Burnet Institute noted that 
forced treatment centers compelled
detainees to take HIV tests, but did
not offer any treatment to the 40 to
80 percent who tested positive. 
Increased options in 2005
In light of these reports, ARV programs can
be said to have failed drug users rather than
the other way around. Accurate assessment
of how many IDUs had access to ARV in
2005 was further complicated by the fact
that many governments did not collect the
information or failed to make it available.
Nonetheless, treatment options for drug
ARV for IDUs
Ten percent of the world’s HIV cases are among IDUs. Yet in nearly all countries—includ-
ing those where they comprise a significant majority of all cases—IDUs have been dis-
proportionately less likely to have access to ARV treatment. In many developing/transi-
tional countries with injection-driven epidemics, ARV has been provided to drug users
last if it is has been offered to them at all. 
History of Neglect
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users clearly improved in 2005 in a number
of developing/transitional countries with
injection-driven epidemics. Grants from the
Global Fund proved particularly important
in allowing the creation of HIV treatment
models more inclusive of IDUs.
In Georgia, authorities report that all
those identified as needing ARV have
access to treatment. While claims of univer-
sal access do not account for those IDUs
afraid of or unable to be tested, it is 
noteworthy that universal access is a goal 
supported by the government, and that
IDUs—nearly 50 percent of those receiving
ARV as of November—receive treatment
somewhat proportionate to their share of
total HIV cases. 
In China, using Global Fund grant
money, authorities have included IDUs
explicitly among those to be reached 
by treatment initiatives providing ARV free
of charge. Some provinces are considering
provision of treatment in compulsory detox-
ification centers.
In Russia, the GLOBUS project, formed
by NGOs with the support of the Global
Fund, launched a treatment initiative in
2005. The GLOBUS model was unusual
because it prioritized inclusion of drug
users in ARV treatment, and recognized the
expertise of peer educators and people with
HIV as well as physicians. The treatment
initiative was guided by the Open Health
Institute, with technical assistance provided
by IHRD and international treatment
experts. More than 70 percent of the 210
patients enrolled by the end of December
2005 were either current or former IDUs. 
voices from the front
A STEP TOWARD EQUITABLE TREATMENT ACCESS
The Strategic Treatment Education Project (STEP), a peer treatment program created by the
European AIDS Treatment Group (EATG) with technical support from IHRD, continued work in
Eastern Europe and expanded to Central Asia in 2005. Under this program, experienced HIV treat-
ment educators train local educators with links to communities where need for treatment is great-
est. Initial training sessions focus on the basics of HIV treatment, case studies, group work, and
problem-solving on treatment protocols, as well as on practical issues like interactions of HIV and
street drugs; treatment of those co-infected with hepatitis C and HIV; and user-friendly perspectives
on ways to increase treatment adherence and diminish negative side effects. STEP trainees are then
linked through the Internet for ongoing education and support with a panel of community educators
using an electronic listserv (STEPnet) moderated by a facilitator.
A training conducted in July 2005 in Bishkek, Kyrgyzstan, brought together 33 treatment educators
and constituted one of the largest gatherings of people with HIV in the history of Central Asia. In addi-
tion, STEP launched its online training course for Central Asian treatment educators in October. The
EATG plans to have the program transition entirely to Russian-speaking regional experts by 2006, and
will continue to emphasize the treatment needs of IDUs. With support from WHO, STEP trainers have
also developed a training manual for a “knowledge hub” on harm reduction, coordinated by the
Central and Eastern European Harm Reduction Network, IHRD, and AIDS Foundation East-West.
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Efforts to control drug users through incar-
ceration, however, only fuel HIV epi-
demics, placing large numbers of infected
and uninfected individuals in environ-
ments where risky behaviors such as drug
use, sex, and tattooing continue but where
means of protection are often unavailable.
In all prisons—whether the special facili-
ties constructed for drug users in Indonesia
or the general facilities where drug users
make up a large number of those impris-
oned in countries like Russia—inmates
report injecting drug use.  Frequently, pris-
oners will share or rent needles that are
homemade, contaminated, or even rusty
with overuse.
The results of the failure to implement
harm reduction in prisons are clear.  
• In Indonesia, a June 2005 assess-
ment by Australian researchers found
that as many as 10 to 20 prisoners
rented a single syringe.  Tattoo nee-
dles, too, were routinely used on as
many as three to five inmates.  
• In Ukraine, a 2004 survey of prison-
ers in six different regions found that
11 percent reported using injection
drugs in the past year, with many
reporting sharing of injecting equip-
ment.
• In Kyrgyzstan, according to Ministry
of Justice reports, half of the country’s
registered HIV cases in 2004 were
among those in prison.
• In Latvia, a 2003 study by the Latvian
Institute of Philosophy and Sociology
found that 14 percent of prisoners
injected in prisons and that 80 
percent of those prisoners shared
needles.
• In Russia, a 2002 study of 10
Russian prisons by Médicins Sans
Frontières found that one in ten 
prisoners reported injecting drugs,
and two-thirds of those who injected
shared needles.  As many as 13 per-
cent injected for the first time while
incarcerated. 
• In Lithuania, an HIV outbreak in
2002 resulted in the diagnosis of 299
HIV cases in Alytus prison, nearly
double the total number diagnosed in
Lithuania in the previous decade.
Steps that can reduce HIV infection 
in prisons have been long acknowledged.
As early as 1993, WHO’s Guidelines 
on HIV Infection and AIDS in Prisons recom-
mended that countries where needle
exchange was offered to IDUs in the com-
munity also provide sterile injection equip-
ment to prisoners during detention and
upon release. In May 2005, WHO Europe
issued its Status Paper on Prisons, Drugs, and
Harm Reduction, noting that “the evidence
Prisons, HIV, and IDUs
Most developing/transitional countries with injection-driven epidemics have responded
to growing drug use by tightening legal controls, and by punishing possession of even
small amounts of drugs with incarceration or forced institutionalization.
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of effectiveness of harm reduction action is
now overwhelming.” Among the report’s
recommendations were that all prison sys-
tems provide opiate substitution treatment
and needle exchange programs equivalent
to those available in the community. The
prestigious medical journal The Lancet, in a
July 2 commentary, called the WHO Europe
paper “one of the most important docu-
ments on prison health ever published.”
Nonetheless, few prisons have imple-
mented these lifesaving recommendations.
Among developing/transitional countries
with injection-driven epidemics, only
Moldova had both needle exchange and
methadone maintenance in prisons in
2005, with methadone going to fewer than
10 prisoners. Belarus provides needle
exchange in a single prison. Indonesia
began limited methadone maintenance
treatment in two prisons in 2005, and
Armenia began needle exchange in three
penal institutions.  Kyrgyzstan has needle
exchange programs in 11 prison colonies.
Iran, which has the largest prison-based
methadone program of any developing/
transitional country with an injection-driven
HIV epidemic, plans to pilot needle
exchange in 2006.  With funds and techni-
cal support from IHRD, the Canadian
International Development Agency, and the
Canadian HIV/AIDS Legal Network, among
others, Ukraine has also pledged to begin
needle exchange in two prison colonies in
2006; experts held trainings and an interna-
tional conference on the subject in 2005. 
These developments notwithstanding,
harm reduction programs in prisons
remained highly limited in the countries
where they were needed most in 2005.
Outside of Iran, fewer than 50 prisoners
had access to substitution treatment in
developing countries where the majority of
HIV cases were among IDUs. Availability of
needle exchange also lagged far behind
need.
Prisoner in cell, Bali, Indonesia
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Harm Reduction in Prisons
Developing/Transitional Countries with Injection-Driven HIV Epidemics, 2005
Central and Eastern Europe and the former Soviet Union 
HIV cases Needle exchange Substitution 
among inmates* availability in prisons treatment 
in prisons
Armenia n/a yes no
Azerbaijan 25 no no
Belarus 2,833 yes (one prison) no
Estonia 420 no no
Georgia n/a no no
Kazakhstan 600 no no
Kyrgyzstan 170 yes no
Latvia 511 no no
Lithuania 254 no no
Moldova 159 yes yes (<10 patients)
Poland 981 no yes (< 25 patients)
Russia 42,000 no no
Tajikistan 60 no no
Turkmenistan n/a no no
Ukraine 4,000 no no
Uzbekistan 56 no no
Asia
HIV cases Needle exchange Substitution 
among inmates* availability in prisons treatment 
in prisons
China n/a no no
Indonesia 8,850 no yes (<25 patients)
Iran n/a yes yes
Malaysia 1,834 no no
Vietnam n/a no no
* Numbers of those with HIV in prisons are highly inaccurate, often reflecting cases detected rather than total numbers of those infected.
n/a = not available
Sources:
HIV estimates: Medical department of national prison authorities (Lithuania, Moldova, and Ukraine), December 2005; UNODC HIV/AIDS unit,
September 2005; (Data collected between 2000-2005). Needle exchange and substitution treatment availability: National prison authorities and
reports to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
FROM RESEARCH TO ACTION ON PRISON NEEDLE EXCHANGE
Health Canada, the UN Office on Drugs and Crime, UNAIDS, and OSI co-sponsored a global
policy dialogue on HIV in prisons in Toronto in October 2005. The meeting brought together high-
level prison officials, representatives from ministries of justice, judicial reformers, and NGOs from
11 countries. James Motherall, a former prisoner and prison advocate, addressed the group. An
excerpt of his remarks follows.
voices from the front
A number of speakers today have men-
tioned the need for studies about the effec-
tiveness of harm reduction. That’s under-
standable, but there have been many stud-
ies already that all say the same things that
prisoners already know. The missing com-
ponent for HIV and hepatitis prevention
among prisoners is action. Some harm
reduction methods are available in prison
[in Canada] such as condoms, bleach for
cleaning needles, methadone programs,
and education. The problem is these meth-
ods do not go far enough.
Corrections Canada has recently
approved pilot projects for tattoo parlors 
in some of its prisons to reduce the spread
of hepatitis. Normally this would be a step
forward except they have said that they
won’t do facial tattoos, numbers, gang
signs, or tattoos that could be viewed as
obscene. These restrictions take away the
kinds of tattoos that prisoners would nor-
mally want done. This means tattoos will
continue to be done underground, consti-
tuting an unsafe practice. 
Corrections has not yet brought in needle
exchange programs. The claim is that to do
so would be condoning the use of drugs or
that syringes could be used as weapons.
Both arguments are not worth the breath it
takes to make them. Drug use in prison
continues to be illegal and those caught
using or smuggling in drugs will still be
subject to whatever sanctions are in place.
With respect to syringes being used as
weapons, the same argument was made
with bleach. The fear was that it would be
thrown in the eyes of staff. That never hap-
pened. As for needles being used as
weapons, why would someone want to use
a needle when there are shivs [homemade
knives] as long as 18 inches already avail-
able?  Also, people say you shouldn’t intro-
duce needles into prison, but there are nee-
dles there already. If people wanted to use
them as weapons they would use the dirty
ones currently there. When guards do pat
downs, or cell searches, it’s a lot more dan-
gerous for them if they get stuck with nee-
dles that have been reused so many times
that they are likely to be infected.
Studies that tell us what the problem 
is do not save lives unless they are acted
upon. The study I want to see is the one
that tells me how successful needle
exchange programs have been in Canada.
That study will mean we did more than talk-
ing, and took action.
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This is not simply a problem of financing.
Substitution treatment often remains
unavailable even in countries where the
Global Fund has pledged support. It is not 
a problem of evidence, since in study 
after study, substitution treatment is shown
to reduce HIV risk, diminish social costs of
drug use such as crime, and increase adher-
ence to HIV treatment. Rather, it is a prob-
lem of mindset and commitment. European
countries have vastly scaled up substitution
treatment in the midst of their HIV epi-
demics—in France, for example, 80,000
patients have received buprenorphine 
treatment since 1996, and some 15,000
patients were receiving methadone in 2005.
Germany legalized methadone treatment 
in 1987 and had about 60,000 patients 
on treatment in 2005. 
Many countries with injection-driven
epidemics, by contrast, have regarded sub-
stitution treatment as an issue of law
enforcement rather than a problem of pub-
lic health. Authorities insist that the risk of
illegal diversion justifies failure to treat, or
erect bureaucratic obstacles that severely
limit scale and restrict service delivery.
Many countries subject substitution treat-
ment projects to “death by pilot,” requiring
them to complete elaborate paperwork,
secure new authorizations from multiple
ministries, and to demonstrate the efficacy 
of their approach year after year.  Imagine 
if heart surgeons were asked to present 
data about the effectiveness of coronary
bypass procedures in every country before
being given permission to operate. The
result in the case of restrictions on substitu-
tion treatment is more HIV infection, more
suffering, and more deaths from overdose
and AIDS.
Signs of progress were evident in 2005.
China, Iran, and Vietnam reinforced 
their commitment to scaling up access to
methadone maintenance treatment among
IDUs as part of their national HIV preven-
tion strategies. By December 2005, 6,500
patients were receiving methadone in
China, and some 3,600 patients were 
on substitution treatment in Iran. Belarus,
Vietnam, and Kazakhstan all authorized
pilots in 2005, and will begin to provide
medication in 2006. More broadly, many of
the developing/transitional countries with
injection-driven epidemics took small but
important steps forward in 2005, initiating
substitution treatment for the first time
with either buprenorphine (Ukraine) or
Substitution Treatment
Medication for the treatment of opiate dependence, known as substitution treatment, 
is common practice in rich nations. In developing/transitional countries with injection-
driven epidemics, substitution treatment remains strikingly inaccessible. Of the nearly
5.2 million IDUs estimated to live in countries where contaminated needles are the main
source of HIV infections, fewer than 13,000 have access to one of the best and best-
researched means of saving lives and controlling HIV infections.
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methadone (Georgia and Malaysia).
Indonesia and Moldova began provision 
of substitution treatment in prisons.
Community advocates helped move the
World Health Organization to add both
methadone and buprenorphine to its list of
essential medicines in June (see page 14).
At the negative end of the scale, substitu-
tion treatment remained illegal in Russia,
one of the countries with the largest HIV
epidemic among IDUs. While laws did not
ban methadone use in Belarus or Ukraine 
in 2005, implementation of that treatment
remained blocked by government opposi-
tion. In Lithuania, a parliamentary commis-
sion on drugs launched a highly publicized
effort to restrict access to methadone.
Advocacy by international experts and local
HIV advocates rebuffed calls to close down
the Lithuanian methadone programs, 
but political opposition and disinformation 
campaigns continued. The majority of
patients there are required to pay for treat-
ment themselves, a factor further limiting
access.
In China, authorities restricted entry 
to methadone to those who had passed
through two institutionalizations in forced
detoxification centers (or one forced detox
and one forced labor camp). In some
provinces, decisions about who entered
treatment were left to the police. 
Even the few countries with injection-
drive epidemics deemed to have low-
threshold, noncoercive, and low-cost access
to methadone have had no success in bring-
ing treatment to scale. For example, in
Poland, despite an estimated 43,000 IDUs,
fewer than 900 had access to methadone, 
a level that has stayed steady even as the
number of HIV cases in the country has
steadily climbed.
Patient receiving methadone, Bishkek, Kyrgyzstan
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Availability of Opiate Substitution Treatment 
Developing/Transitional Countries with Injection-Driven HIV Epidemics, December 2005
Central and Eastern Europe and the former Soviet Union
Estimated IDU  Total number   Total number  Total number
population of clients on of clients on of clients on
methadone buprenorphine substitution
treatment
Armenia 9,000 0 0 0
Azerbaijan 19,000 80 0 80
Belarus 46,000 0 0 0
Estonia 20,000 332 n/a 332*
Georgia 12,000 8 0 8
Kazakhstan 174,000 0 0 0
Kyrgyzstan 21,000 83 0 83
Latvia 11,000 55 0 55*
Lithuania 8,000 400 0 400*
Moldova 97,000 21 0 21
Poland 43,000 885 0 885
Russia 1,977,000 0 0 0
Tajikistan 53,000 0 0 0
Turkmenistan 11,000 0 0 0
Ukraine 397,000 0 165 165
Uzbekistan 87,000 0 0 0
Total CEE/FSU 2,985,000 1864 165 2,029
* As of November 2005
n/a = not available
Note: Numbers do not include maintenance treatment prescribed by general practitioners or outpatient psychiatric units. In some countries such prescriptions are quite extensive. 
Sources:
IDU estimates:  UNODC HIV/AIDS Unit, September 2005 (midpoint estimates). Data collected from 2000-2004.
Substitution treatment:  National AIDS/narcological centers and Soros foundations (CIS countries); the Central and Eastern European Harm Reduction Network (Baltics and Belarus); 
the Krakow Association for Drug User Support (Poland); and the AIDS Outreach Program (Moldova).
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Availability of Opiate Substitution Treatment 
Developing/Transitional Countries with Injection-Driven HIV Epidemics, December 2005
Asia
Estimated IDU  Total number   Total number  Total number
population of clients on of clients on of clients on
methadone buprenorphine substitution
treatment
China* 1,093,000 6,500 0 6,500
Indonesia** 580,000 ~400 n/a, for detox only ~400
Iran 206,000 3,600 0 3,600
Malaysia 195,000 350 26 376 
Vietnam 113,000 0 0 0
Total Asia 2,187,000 10,850 26 10,876
* China figures exclude Hong Kong and Macao
** As of July 2005
n/a = not available
Note: Numbers do not include maintenance treatment prescribed by general practitioners or outpatient psychiatric units. In some countries such prescriptions are quite extensive. In Malaysia, for
example, pharmaceutical companies reported 2,500 methadone prescriptions in 2001, and as many as 15,000 for buprenorphine.
Sources:
IDU estimates:  UNODC HIV/AIDS Unit, September 2005 (midpoint estimates). Data collected from 2000-2004.
Substitution treatment: European Network on Drugs and Infections in Prison; the Malaysian AIDS Council; and local programs. 
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Founded in 1995, the International Harm
Reduction Development Program (IHRD) of the
Open Society Institute (OSI) works to reduce
HIV and other harms related to injecting drug
use, and to press for policies that reduce
stigmatization of illicit drug users and protect
their human rights. IHRD, which has support-
ed more than 200 programs in Central and
Eastern Europe, the former Soviet Union, and
Asia, bases its activities on the philosophy
that people unable or unwilling to abstain
from drug use can make positive changes to
protect their health and the health of others.
Since 2001, IHRD has prioritized advocacy to
expand availability of needle exchange, opiate
substitution treatment, and treatment for HIV;
to reform discriminatory policies and prac-
tices; and to increase the political participa-
tion of people who use drugs and those living
with HIV.
www.soros.org/harm-reduction
